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Introduction
 | Chapter 18
Huntington’s disease 
Huntington’s disease (HD) is an autosomal dominant, progressive neurodegenerative 
disorder characterized by motor disturbances, cognitive decline, psychiatric symptoms, 
and functional disability. It is caused by a cytosine-adenine-guanine (CAG) trinucleotide 
repeat expansion in the Huntingtin gene on chromosome 4.1 A CAG expansion of 36 
repeats or more is associated with HD, although only a CAG repeat length of 40 or more is 
considered fully penetrant and will cause HD inevitably.2 The mean age of disease onset is 
30-50 years, with a mean disease duration of 17-20 years.3 Age of onset is inversely 
correlated to CAG repeat length.4,5 Brain atrophy is most pronounced in the caudate 
nucleus and putamen of the striatum.6 Atrophy is already detectable before disease onset 
and progresses throughout the course of the disease.7 
HD is a rare disorder with a prevalence of 5-10 per 100,000 in the Caucasian population.3 
In the Netherlands, the total number of HD patients is approximately 1,700. About 6,000 
to 9,000 people are at risk for developing HD. Genetic testing is available for individuals at 
risk. This test can identify premanifest gene carriers, who do not show symptoms or signs 
of HD yet, but will develop HD in the future. After disease onset, patients are referred to 
as manifest. Severity of HD progresses from early stage HD to late stage HD over time.8 
 
Clinical features 
HD is clinically characterized by a triad of motor, cognitive, and behavioral symptoms. The 
most distinctive motor symptom of HD is chorea; involuntary, irregular movements of the 
face, trunk, and limbs. Other motor symptoms include bradykinesia, dystonia, impairment 
of oculomotor function, and gait/balance problems. As the disease progresses, chorea 
tend to decline, while dystonia, bradykinesia, dysarthria and dysphagia become more 
prominent.3,9 Cognitive decline is another sign of HD. Typically, impairment in executive 
functioning, memory, and psychomotor speed arise in HD.10 The third main clinical feature 
of HD is behavioral change. Frequently reported psychiatric symptoms are depression, 
anxiety, irritability, and apathy.11 Depression and anxiety are common in the mild-to-
moderate disease severity stages, while apathy is especially prevalent in more advanced 
severity stages.12-15 
HD is presently incurable and it is not possible to delay either onset or progression of the 
disease. Due to the progressive nature of the disease, the clinical features ultimately lead 
to functional decline and loss of independency. As a result, it becomes more difficult for 
care to be provided at home, which may lead to nursing home admission. 
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Assessment scales 
Multiple rating scales and instruments to detect and monitor the severity and progression 
of clinical features in HD have been developed over the years. Some assessment scales, 
such as the Unified Huntington’s Disease Rating Scale (UHDRS) and the Unified 
Huntington’s Disease Rating Scale-For Advanced Patients (UHDRS-FAP), have a categorical 
and semi-quantitative design.16,17 Other measurement instruments, such as eye-tracking 
equipment, tongue force analysis, and quantitative-motor (Q-Motor) assessments, have a 
continuous, quantitative, and more objective design.18-20 
The clinical assessment of symptoms and signs in HD is usually performed with the UHDRS, 
developed by the Huntington Study Group (HSG).16 The UHDRS is divided into four 
domains: motor performance, cognitive function, behavioral abnormalities, and functional 
abilities. The motor section assesses chorea, dystonia, eye movements, 
bradykinesia/rigidity, and gait/balance. Cognitive function is measured by the Verbal 
Fluency test, the Symbol Digit Modalities test, and the Stroop test (color naming, word 
reading, and interference).21-23 The behavioral domain comprises depression, anxiety, 
irritability/aggression, obsessive-compulsive behaviors, psychosis, and apathy. Functional 
ability is assessed by the Total Functional Capacity (TFC), the Functional Assessment Scale 
(FAS), and the Independence Scale (IS). The UHDRS has been developed to follow 
individual patients systematically over time, and monitor disease progression for both 
research purposes and for use in clinical practice. The motor, cognitive, and functional 
domains of the UHDRS have demonstrated to be sensitive to detect longitudinal changes 
in manifest HD patients.16,24-28 
In late stage HD, ceiling and floor effects of the UHDRS hamper the detection of changes 
and, therefore, disease progression is difficult to measure in patients with advanced 
HD.28,29 For this reason, the UHDRS-FAP has been developed.17 This scale consists of four 
sections, which are a motor, cognitive, somatic, and behavioral section. The items of the 
domains are adjusted for more severely affected patients. 
 
This thesis 
The main aim of this thesis was to investigate different measurement properties of the 
UHDRS and UHDRS-FAP in various severity stages of HD. The UHDRS is widely used in 
therapeutic clinical trials in HD and the motor domain, which is also called the Total Motor 
Score (TMS), often serves as primary endpoint to assess efficacy of interventions. 
Therefore, a high interrater reliability is desirable to determine the course of the motor 
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symptoms over time. A teaching video has been developed by the European Huntington’s 
Disease Network (EHDN), in collaboration with the HSG, and an annual online certification 
has been implemented for this purpose in 2009.30 In chapter 2, we aimed to investigate 
the interrater reliability of the UHDRS-TMS and of its subitems, using the ratings of the 
online certification. We also examined the impact of the annual certification on rater 
performance. In chapter 3, we focus on the oculomotor items of the UHDRS-TMS. The aim 
was to find out which of these items were affected in premanifest gene carriers compared 
to healthy controls and might be useful for detecting early clinical signs of HD. 
In advanced stages of HD, knowledge is limited about the course of the clinical 
manifestations. Hardly any information on sensitive disease outcome measures to track 
disease progression is available and guidelines for management and care in long-term care 
facilities are limited.31 Therefore, we aimed to explore the properties of the UHDRS-FAP 
and UHDRS in patients with advanced HD residing in a nursing home or receiving day-care. 
We investigated the capacity of the scales to differentiate between patients in the later 
stages of the disease using our cross-sectional data (chapter 4). Internal consistency and 
interrater reliability of both scales are also reported. The rating scales were administered 
again after six months. With our longitudinal data, we examined if the UHDRS-FAP and 
UHDRS could detect disease progression in patients with late stage HD (chapter 5). In 
chapter 6, we aimed to identify predictors for institutionalization by examining differences 
between nursing home residents and day-care patients with HD. Identification of 
predictors may lead to interventions and treatment strategies that can postpone the need 
for nursing home admission. In the final chapter (chapter 7), we discuss our conclusions 
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CHAPTER 2  
Interrater reliability of the 
Unified Huntington’s Disease Rating Scale- 
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Abstract 
Background: The clinical assessment of motor symptoms in Huntington’s disease is usually 
performed with the Unified Huntington’s Disease Rating Scale-Total Motor Score (UHDRS-
TMS). A high interrater reliability is desirable to monitor symptom progression. Therefore, 
a teaching video and a system for annual online certification has been developed and 
implemented. 
Objectives: The aim of this study is to investigate the interrater reliability of the UHDRS-
TMS and of its subitems, and to examine the performance of raters in consecutive years. 
Methods: Data from the online UHDRS-TMS certification were used. The interrater 
reliability was assessed for all first-time participants (n = 944) between 2009 and 2016. 
Intraclass correlation coefficients (ICC) were calculated for each year separately and the 
mean was taken as the total ICC. 
Results: The UHDRS-TMS (ICC = 0.847), tandem walking (0.824), pronate/supinate hands 
left (0.713), and retropulsion pull test (0.706) showed good interrater reliability. Poor 
interrater reliability was found for maximal dystonia of the left and right upper extremity 
(0.187 and 0.322, respectively), maximal dystonia of the left and right lower extremity 
(0.200 and 0.256, respectively), and maximal dystonia of the trunk (0.389), tongue 
protrusion (0.266), and rigidity arms left (0.390). Raters performed significantly worse on 
follow-up certification compared to their first certification. 
Conclusions: Our results suggest that the rating of dystonia (absent, slight, mild, 
moderate, or marked) is subjective and difficult to interpret, especially on video. 
Therefore, changing the dystonia items of the UHDRS-TMS should be explored. We also 
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Huntington’s disease (HD) is an autosomal dominant, progressive neurodegenerative 
disorder characterized by motor disturbances, cognitive decline, psychiatric symptoms 
and functional disability.1 It is caused by a cytosine-adenine-guanine (CAG) trinucleotide 
repeat expansion on chromosome 4 in the Huntingtin gene.2 The mean age at disease 
onset is between 30 and 50 years.3 
The clinical assessment of symptoms and signs in HD is usually performed with the Unified 
Huntington’s Disease Rating Scale (UHDRS), developed by the Huntington Study Group 
(HSG).4 The UHDRS assesses four domains: motor function, cognitive function, behavioral 
abnormalities, and functional capacity. It was developed to follow individual patients 
systematically over time and monitor disease progression for both research purposes and 
for use in clinical practice. The sensitivity of the scale to detect longitudinal changes has 
been demonstrated by observational studies in manifest HD patients. In particular, the 
Total Motor Score (TMS) and the Total Functional Capacity (TFC) have been shown to 
deteriorate significantly during one-year follow-up.4-9 
The UHDRS is widely used in therapeutic clinical trials in HD and the UHDRS-TMS often 
serves as primary endpoint to assess efficacy of interventions. Therefore, a high interrater 
reliability is desirable to determine the course of the motor symptoms over time. Available 
data suggest that the interrater reliability of the TMS is high, with an intraclass correlation 
coefficient of 0.94.4 
In order to establish a high interrater reliability of the UHDRS-TMS, the European 
Huntington’s Disease Network (EHDN), in collaboration with the HSG, developed a 
teaching video for the UHDRS-TMS and established an annual online system of UHDRS-
TMS certification.10,11 Despite this effort, we hypothesize that several items of the TMS are 
highly subjective and difficult to score. We therefore aim to investigate the interrater 
reliability of the UHDRS-TMS and of its subitems in the large database of ratings 
performed for annual online certification. We also aim to examine the impact of annual 
certification on rater performance to assess if certification increases accuracy over time. 
 
Methods 
Certification, which only involves the motor section of the UHDRS (not the cognitive, 
behavioral and functional domains) is mandatory for all individuals who carry out the 
motor section of the UHDRS in clinical trials. The UHDRS-TMS consists of 31 items (Table 
1), with varying response options ranging from zero (normal/not affected) to four (cannot 
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perform/severely affected; see Supplement 1 for all response options per item). Hence, 
the total range of the UHDRS-TMS is 0 to 124. Higher scores generally indicate more 
severe motor impairment. Data from the annual UHDRS-TMS online certification were 
used for this study. The procedure consists of assessing three videos of patients with HD 
and providing the UHDRS-TMS ratings. In order to pass certification, it is necessary to rate 
at least two of the three videos correctly, which means 24 out of the 31 items must be 
rated correctly, the range of acceptable answers being defined by a panel of EHDN and 
HSG experts. If a rater fails, he is given the chance to rate a new set of three videos, but if 
he fails again, he will not be certified to perform the UHDRS-TMS and will be referred for 
further expert training. 
UHDRS-TMS certification started in 2009.10 The present study includes the first attempt of 
each rater in each year between 2009 and 2016. In 2012, biannual certification was 
proposed and implemented, but was soon reversed, with annual certification resuming in 
2014. Therefore, the raters who participated in 2012 did not have to perform the 
certification in 2013, and the raters who participated in 2013 scored the same three 
videos as the raters who participated in 2012. 
Statistical analysis was performed using IBM Statistical Package for the Social Sciences 
(SPSS) version 23. The interrater reliability of the UHDRS-TMS and its subitems was 
assessed for all first attempts with the intraclass correlation coefficient (ICC). We used a 
two-way random model with absolute agreement. ICC values were calculated for each 
year separately and the mean of this ICC was taken as the total ICC. An ICC higher than 0.7 
was defined as good; a value lower than 0.4 was considered poor.12,13 The percentage of 
raters who scored the separate motor items of the UHDRS correctly was determined using 
all first efforts. This was compared to the range of acceptable answers defined by the 
panel of HD experts. Follow-up performance was based on the results of raters who had 
carried out at least one rating, one year after their first participation. Because videos in 
consecutive years might differ in difficulty, we also assessed the follow-up of raters who 
participated for the first time in 2010 and again in 2012, years in which the same three 
videos were used. The raters were not informed about the use of the same videos. The 
percentage of UHDRS motor items rated correctly was calculated per certification, and 
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The total number of examinations performed between 2009 and 2016 was 1,982 and the 
number of first participations was 944, therefore many raters participated multiple times. 
The majority of raters in this study were physicians with different levels of expertise; 
however, nurses and other health care professionals also took part. The interrater 
reliability of the UHDRS-TMS, the separate subitems, and the total dystonia and chorea 
scores is shown in Table 1. The mean UHDRS-TMS of all videos was 31.9 (range 0 to 82). 
ICC values were high for the TMS (0.847), tandem walking (0.824), pronate/supinate 
hands left (0.713), and retropulsion pull test (0.706). Low ICC values were found for 
maximal dystonia of the left and right upper extremity (LUE and RUE; 0.187 and 0.322, 
respectively), maximal dystonia of the left and right lower extremity (LLE and RLE; 0.200 
and 0.256, respectively), maximal dystonia of the trunk (0.389), tongue protrusion (0.266), 
and rigidity arms left (0.390). 
For every subitem of the UHDRS-TMS, we calculated the percentage of raters who rated 
the item within the accepted range at their first participation (Table 1). Often, the expert 
panel defined more than one answer as correct, and therefore the mean number of 
options defined as correct is also reported. Gait (95.8%), retropulsion pull test (95.2%), 
dysarthria (94.1%), finger taps left (93.0%), and maximal chorea of the trunk (90.5%) were 
the items that were most often rated correctly. Saccade velocity vertical (76.5%), saccade 
velocity horizontal (76.8%), maximal chorea LUE (76.8%), luria (77.4%), and maximal 
chorea RUE (78.5%) were more difficult to score. 
 
Table 1. Interrater reliability for all UHDRS-TMS items at first participation (n = 944) 










1. Ocular pursuit horizontal 0.623 (0.509-0.737) 83.9% 2.0 
2. Ocular pursuit vertical 0.662 (0.591-0.732) 84.7% 2.1 
3. Saccade initiation horizontal 0.592 (0.462-0.721) 83.7% 2.1 
4. Saccade initiation vertical 0.610 (0.413-0.807) 84.5% 2.0 
5. Saccade velocity horizontal 0.591 (0.431-0.751) 76.8% 2.0 
6. Saccade velocity vertical 0.564 (0.438-0.689) 76.5% 2.3 
7. Dysarthria 0.452 (0.208-0.695) 94.1% 1.6 
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8. Tongue protrusion 0.266 (-0.031-0.562) 83.5% 1.2 
9. Finger taps right 0.413 (0.114-0.711) 84.3% 1.7 
10. Finger taps left 0.569 (0.310-0.828) 93.0% 1.9 
11. Pronate/supinate hands right 0.598 (0.375-0.821) 88.8% 1.5 
12. Pronate/supinate hands left 0.713 (0.547-0.879) 88.9% 1.7 
13. Luria 0.478 (0.188-0.768) 77.4% 1.3 
14. Rigidity arms right 0.598 (0.518-0.678) 89.4% 1.7 
15. Rigidity arms left 0.390 (0.174-0.607) 89.2% 1.5 
16. Bradykinesia body 0.588 (0.454-0.723) 87.4% 2.1 
17. Maximal dystonia trunk 0.389 (0.277-0.500) 87.7% 1.9 
18. Maximal dystonia RUE 0.322 (0.095-0.549) 86.7% 1.7 
19. Maximal dystonia LUE 0.187 (0.058-0.316) 83.8% 1.7 
20. Maximal dystonia RLE 0.256 (0.134-0.377) 83.8% 1.7 
21. Maximal dystonia LLE 0.200 (0.061-0.338) 83.3% 1.7 
22. Maximal chorea face 0.597 (0.516-0.677) 88.7% 2.1 
23. Maximal chorea BOL 0.551 (0.415-0.687) 86.5% 2.2 
24. Maximal chorea trunk 0.685 (0.541-0.829) 90.5% 2.1 
25. Maximal chorea RUE 0.508 (0.359-0.657) 78.5% 1.9 
26. Maximal chorea LUE 0.446 (0.213-0.679) 76.8% 1.9 
27. Maximal chorea RLE 0.572 (0.447-0.696) 85.1% 2.1 
28. Maximal chorea LLE 0.615 (0.499-0.732) 89.6% 2.1 
29. Gait 0.642 (0.421-0.864) 95.8% 1.6 
30. Tandem walking 0.824 (0.693-0.955) 88.1% 1.4 
31. Retropulsion pull test 0.706 (0.524-0.888) 95.2% 1.4 
UHDRS-TMS 0.847 (0.766-0.928) NA NA 
Total dystonia score 0.369 (0.182-0.555) NA NA 
Total chorea score 0.670 (0.516-0.825) NA NA 
ICC values were calculated using a two-way random model with absolute agreement. ICC values were 
calculated for each year separately and the mean of this ICC was taken as the total ICC (with 95% CI). 
Abbreviations: BOL, buccal-oral-lingual; CI, confidence interval; ICC, intraclass correlation coefficient; LLE, left 
lower extremity; LUE, left upper extremity; NA, not applicable; RLE, right lower extremity; RUE, right upper 
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Table 2. Performance of raters on the UHDRS-TMS certification over time 
 Percentage of UHDRS-TMS 
items scored correctly 
p-value 
First certification (n = 226) 86.6% (±6.3) 0.004 
Second certification one year later (n = 226) 85.1% (±6.7)   
First certification in 2010 (n = 81) 87.8% (±5.0) 0.045 
Same certification in 2012 (n = 81) 86.4% (±6.3)  
Data are mean (with standard deviation). p-values were calculated using paired sample t-tests. 
Abbreviations: UHDRS-TMS, Unified Huntington's Disease Rating Scale-Total Motor Score. 
 
The performance of raters on the UHDRS-TMS certification over time is presented in Table 
2. The number with one or more follow-up participations one year after their first rating 
was 226. At their first examination, the raters scored 86.6% of the motor subitems 
correctly. One year later, at their second certification, the score dropped significantly to 
85.1% (p = 0.004). Eighty-one raters participated for the first time in 2010 and saw the 
same three videos in 2012. The percentage of items scored correctly dropped significantly 
from 87.8% in 2010 to 86.4% in 2012 (p = 0.045). 
 
Discussion 
This study in a large cohort of raters showed a good interrater reliability of the UHDRS-
TMS. We found an intraclass correlation coefficient of 0.847, which is lower than the ICC 
of 0.94, previously reported by the HSG.4 An even higher ICC of 0.97 was found in patients 
with advanced HD.14 An important difference between the previously mentioned studies 
and our study is that we examined patients using videos instead of performing an actual 
physical examination. This may have caused differences in rating certain motor items, 
especially rigidity. Muscle tone can only be felt when examining the patient physically and 
cannot be seen on a video. When examining patients using video recordings, one might 
expect a better interrater reliability, because the clinical presentation of the patients is 
standardized and does not vary. However, our study did not show this. An important 
explanation for the lower interrater reliability of the UHDRS-TMS in our study compared 
to the study by the HSG is more than likely the fact that the raters involved in our study 
had variable levels of experience, and were not all HD experts. However, the results of our 
study are probably more relevant, as raters in clinical trials are likely to be more junior. 
The higher ICC reported by the HSG may also be caused by the limited number of raters 
involved. 
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When we investigated the subitems of the UHDRS-TMS, we found a good interrater 
reliability for tandem walking, pronate/supinate hands left, and retropulsion pull test. To 
our knowledge no other study investigated the interrater reliability of the subitems of the 
UHDRS-TMS. However, the HSG did provide the ICC for the total chorea score (i.e., 0.82), 
and for the total dystonia score (i.e., 0.62).4 These ICC values are also higher than the ICC 
values for the total chorea score and total dystonia score in our study (0.670 and 0.369, 
respectively). Especially, the subitems maximal dystonia LUE, maximal dystonia LLE, and 
maximal dystonia RLE showed poor interrater reliability in our analysis. We also found low 
interrater reliability for tongue protrusion. This is an unexpected result, because this item 
is characterized by clear cutoffs for each category, partly based on time, which is an 
objective measure. Perhaps the poor interrater reliability is caused by the difficulty of 
determining if the tongue is fully protruded or not. 
Our study showed that all dystonia items of the UHDRS-TMS exhibit poor interrater 
reliability, suggesting that the rating of dystonia (absent, slight, mild, moderate, or 
marked) is rather subjective and very difficult to interpret, especially on video. Removing 
or changing (part of) the dystonia items or providing clearer response options should 
therefore be explored, especially because poor interrater reliability hampers monitoring 
HD progression in both individual patients and clinical trials. Siesling et al. performed a 
factor analysis on the UHDRS-TMS.15 They found a Cronbach’s alpha of 0.966 for the 
UHDRS-TMS. When they omitted all dystonia items, the value rose slightly, suggesting that 
the internal consistency of the UHDRS-TMS is still high without dystonia. However, the 
motor phenotype in HD is not homogenous and dystonia-predominant HD (in contrast to 
chorea-predominant HD) is present in some patients.16 Accordingly, the dystonia items 
cannot be removed from the UHDRS-TMS entirely, since this would hamper the content 
validity of the scale. It is worth pointing out that the chorea items have the same scoring 
(absent, slight, mild, moderate, or marked) as the dystonia items. Nonetheless, the 
interrater reliability of the chorea items was better, possibly due to the fact that chorea is 
more common than dystonia in HD, particularly in patients in the earlier stages of HD seen 
regularly in out-patient clinics. Raters may therefore have more experience with different 
levels of severity of chorea. The ICC value of 0.62 for the total dystonia score found by the 
HSG demonstrated moderate interrater reliability and also suggested that dystonia is 
more difficult to score than chorea, as the ICC for the total chorea score was 0.82.4 
Furthermore, the UHDRS-TMS consists of five dystonia items that comprise 16% of the 
total motor score. Taking into account the poor interrater reliability for the dystonia items, 
we suggest reducing or combining the number of dystonia items. The same could be 
applied to the seven chorea items. Future studies are required to explore how the items 
can be improved. 
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UHDRS-TMS. When they omitted all dystonia items, the value rose slightly, suggesting that 
the internal consistency of the UHDRS-TMS is still high without dystonia. However, the 
motor phenotype in HD is not homogenous and dystonia-predominant HD (in contrast to 
chorea-predominant HD) is present in some patients.16 Accordingly, the dystonia items 
cannot be removed from the UHDRS-TMS entirely, since this would hamper the content 
validity of the scale. It is worth pointing out that the chorea items have the same scoring 
(absent, slight, mild, moderate, or marked) as the dystonia items. Nonetheless, the 
interrater reliability of the chorea items was better, possibly due to the fact that chorea is 
more common than dystonia in HD, particularly in patients in the earlier stages of HD seen 
regularly in out-patient clinics. Raters may therefore have more experience with different 
levels of severity of chorea. The ICC value of 0.62 for the total dystonia score found by the 
HSG demonstrated moderate interrater reliability and also suggested that dystonia is 
more difficult to score than chorea, as the ICC for the total chorea score was 0.82.4 
Furthermore, the UHDRS-TMS consists of five dystonia items that comprise 16% of the 
total motor score. Taking into account the poor interrater reliability for the dystonia items, 
we suggest reducing or combining the number of dystonia items. The same could be 
applied to the seven chorea items. Future studies are required to explore how the items 
can be improved. 
For each motor item of the UHDRS, we calculated how many raters scored the item 
correctly at their first participation. Gait, retropulsion pull test, dysarthria, finger taps left, 
and maximal chorea of the trunk were rated best. More difficult items were saccade 
velocity vertical, saccade velocity horizontal, maximal chorea LUE, luria, and maximal 
chorea RUE. However, since the number of options defined as correct was different per 
subitem (due to the fact that different patients were scored in different years), the 
interpretation of which items are easy or more difficult to score is complicated and should 
be interpreted with caution. For example, only 76.5% of the raters scored saccade velocity 
vertical correctly. Even so, the mean number of options defined as correct by the expert 
panel was high for this item, namely 2.3. On the other hand, only 77.4% of the raters 
scored luria correctly, but the mean number of correct options for luria was low (1.3). This 
suggests that saccade velocity vertical is indeed a difficult item to score, but the low 
percentage of raters who scored luria correctly might be low due to the small number of 
options defined as correct. 
We also assessed the performance of raters on the UHDRS-TMS certification 
longitudinally. The percentage of motor items scored correctly dropped significantly 
between the first and second certification one year later. One explanation might be that 
the videos used were not all of the same level of difficulty. Therefore, we also evaluated 
the performance of those raters who scored identical videos in 2010 and 2012, without 
this being announced beforehand. Interestingly, the percentage of motor items scored 
correctly also decreased significantly when re-rating the same patients. However, a 
decrease of 1.4% seems to be only marginally relevant. Apparently slight deviations in 
performing and rating the UHDRS-TMS developed over time. Perhaps raters watched the 
teaching video prior to their first certification, but not two years later. We recommend 
that raters should watch the teaching video before each certification to be reminded of 
the established standards. We also tried to examine the intrarater reliability of the 
subitems of the UHDRS-TMS for those who scored the same videos in 2010 and 2012. 
However, because of low variance between the raters, the intrarater reliability could not 
be calculated with meaningful values. This typically happens when the between-rater 
variation is relatively small compared to the within-rater variation due to a large number 
of different raters. As a result the ICC values turn out to be negative and not interpretable. 
The strength of our study lies in the large cohort of raters who participated in the UHDRS-
TMS certification. The online system allowed us to perform analyses with much higher 
precision and power, since the same video (i.e., standardized clinical presentation) was 
rated by a large number of raters, not just two or three. However, because a patient’s 
clinical presentation usually varies, the use of video recordings is also a limitation of our 
study. Furthermore, some clinical signs might not be captured as easily on video 
compared to direct examination of an actual patient. Ideally, intrarater reliability based on 
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video and direct examination of the same patients should be investigated as it may 
identify those items that are most influenced by this. Another limitation is the fact that 
the ratings used to analyse the interrater reliability were not performed for this purpose, 
but for the purpose of obtaining a certification. Furthermore, we have already 
acknowledged that the clinical stage of patients shown, and thus the level of difficulty of 
the videos used in consecutive years, was not the same. This may have influenced the 
results. However, in real life, the clinical stages of HD patients also differ, which can make 
the UHDRS-TMS rating easier in some patients compared to others. In this study, it is 
important to note that our primary aim was to assess reliability, not validity. Both 
parameters are important for the final judgement of scales and to assess if removal of 
items would improve the scale. 
In conclusion, our study found a good interrater reliability of the UHDRS-TMS. However, 
all dystonia items, together with tongue protrusion and rigidity arms left, showed poor 
interrater reliability. This suggests that the rating of these items is difficult to interpret, 
probably as a consequence of the subjective nature of the response options. Therefore, 
removing, changing, or combining some of the dystonia items, or providing clearer 
response options should be explored, as poor interrater reliability may have a serious 
negative impact on assessing progression of HD motor symptoms in both individual 
patients and clinical trials. Furthermore, the percentage of UHDRS-TMS subitems scored 
correctly dropped significantly between the first and follow-up certification. We, 
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Supplement 1. The Unified Huntington's Disease Rating Scale-Total Motor Score 
1. Ocular pursuit 0 = complete (normal) 2. Ocular pursuit 0 = complete (normal) 
horizontal 1 = jerky movement vertical 1 = jerky movement 
 2 = interrupted pursuit/full 
range 
 2 = interrupted pursuit/full 
range 
 3 = incomplete range  3 = incomplete range 
 4 = cannot pursue  4 = cannot pursue 
3. Saccade initiation 0 = normal 4. Saccade initiation 0 = normal 
horizontal 1 = increased latency only vertical 1 = increased latency only 
 2 = suppressible blinks or 
head movements to initiate 
 2 = suppressible blinks or 
head movements to initiate 
 3 = unsuppressible head 
movements 
 3 = unsuppressible head 
movements 
 4 = cannot initiate saccades  4 = cannot initiate saccades 
5. Saccade velocity 0 = normal 6. Saccade velocity 0 = normal 
horizontal 1 = mild slowing vertical 1 = mild slowing 
 2 = moderate slowing  2 = moderate slowing 
 3 = severely slow, full range  3 = severely slow, full range 
 4 = incomplete range  4 = incomplete range 
7. Dysarthria 0 = normal 8. Tongue 
protrusion 
0 = can hold tongue fully 
protruded for 10 seconds 
 1 = unclear, no need to repeat  1 = cannot keep fully 
protruded for 10 seconds 
 2 = must repeat to be 
understood 
 2 = cannot keep fully 
protruded for 5 seconds 
 3 = mostly incomprehensible  3 = cannot fully protrude 
tongue 
 4 = anarthria  4 = cannot protrude tongue 
beyond lips 
9. Finger taps right 0 = normal (≥15/5 seconds) 10. Finger taps left 0 = normal (≥15/5 seconds) 
 1 = mild slowing, reduction in 
amplitude (11-14/5 seconds) 
 1 = mild slowing, reduction in 
amplitude (11-14/5 seconds) 
 2 = moderately impaired (7-
10/5 seconds) 
 2 = moderately impaired (7-
10/5 seconds) 
 3 = severely impaired (3-6/5 
seconds) 
 3 = severely impaired (3-6/5 
seconds) 
 4 = can barely perform task 
(0-2/5 seconds) 
 4 = can barely perform task 
(0-2/5 seconds) 
11. Pronate/ 0 = normal 12. Pronate/ 0 = normal 
supinate hands right 1 = mild slowing and/or 
irregular 
supinate hands left 1 = mild slowing and/or 
irregular 
 2 = moderate slowing and 
irregular 
 2 = moderate slowing and 
irregular 
 3 = severe slowing and 
irregular 
 3 = severe slowing and 
irregular 
 4 = cannot perform  4 = cannot perform 
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(0-2/5 seconds) 
 4 = can barely perform task 
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11. Pronate/ 0 = normal 12. Pronate/ 0 = normal 
supinate hands right 1 = mild slowing and/or 
irregular 
supinate hands left 1 = mild slowing and/or 
irregular 
 2 = moderate slowing and 
irregular 
 2 = moderate slowing and 
irregular 
 3 = severe slowing and 
irregular 
 3 = severe slowing and 
irregular 
 4 = cannot perform  4 = cannot perform 
13. Luria 0 = ≥4 in 10 seconds, no cue 14. Rigidity arms 0 = absent 
 1 = <4 in 10 seconds, no cue right 1 = slight or present only with 
activation 
 2 = ≥4 in 10 seconds with cues  2 = mild to moderate 
 3 = <4 in 10 seconds with cues  3 = severe, full range of 
motion 
 4 = cannot perform  4 = severe with limited range 
15. Rigidity arms 0 = absent 16. Bradykinesia 0 = absent 
left 1 = slight or present only with 
activation 
body 1 = minimally slow (?normal) 
 2 = mild to moderate  2 = mildly but clearly slow 
 3 = severe, full range of 
motion 
 3 = moderately slow, some 
hesitation 
 4 = severe with limited range  4 = markedly slow, long 
delays in initiation 
17. Maximal 0 = absent 18. Maximal 0 = absent 
dystonia trunk 1 = slight/intermittent dystonia RUE 1 = slight/intermittent 
 2 = mild/common or 
moderate/intermittent 
 2 = mild/common or 
moderate/intermittent 
 3 = moderate/common  3 = moderate/common 
 4 = marked/prolonged  4 = marked/prolonged 
19. Maximal 0 = absent 20. Maximal 0 = absent 
dystonia LUE 1 = slight/intermittent dystonia RLE 1 = slight/intermittent 
 2 = mild/common or 
moderate/intermittent 
 2 = mild/common or 
moderate/intermittent 
 3 = moderate/common  3 = moderate/common 
 4 = marked/prolonged  4 = marked/prolonged 
21. Maximal 0 = absent 22. Maximal chorea 0 = absent 
dystonia LLE 1 = slight/intermittent face 1 = slight/intermittent 
 2 = mild/common or 
moderate/intermittent 
 2 = mild/common or 
moderate/intermittent 
 3 = moderate/common  3 = moderate/common 
 4 = marked/prolonged  4 = marked/prolonged 
23. Maximal chorea 0 = absent 24. Maximal chorea 0 = absent 
BOL 1 = slight/intermittent trunk 1 = slight/intermittent 
 2 = mild/common or 
moderate/intermittent 
 2 = mild/common or 
moderate/intermittent 
 3 = moderate/common  3 = moderate/common 
 4 = marked/prolonged  4 = marked/prolonged 
25. Maximal chorea 0 = absent 26. Maximal chorea 0 = absent 
RUE 1 = slight/intermittent LUE 1 = slight/intermittent 
 2 = mild/common or 
moderate/intermittent 
 2 = mild/common or 
moderate/intermittent 
 3 = moderate/common  3 = moderate/common 
 4 = marked/prolonged  4 = marked/prolonged 
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27. Maximal chorea 0 = absent 28. Maximal chorea 0 = absent 
RLE 1 = slight/intermittent LLE 1 = slight/intermittent 
 2 = mild/common or 
moderate/intermittent 
 2 = mild/common or 
moderate/intermittent 
 3 = moderate/common  3 = moderate/common 
 4 = marked/prolonged  4 = marked/prolonged 
29. Gait 0 = normal gait, narrow base 30. Tandem walking 0 = normal for 10 steps 
 1 = wide base and/or slow  1 = 1 to 3 deviations from 
straight line 
 2 = wide base and walks with 
difficulty 
 2 = >3 deviations 
 3 = walks only with assistance  3 = cannot complete 
 4 = cannot attempt  4 = cannot attempt 
31. Retropulsion 0 = normal   
pull test 1 = recovers spontaneously   
 2 = would fall if not caught   
 3 = tends to fall 
spontaneously 
  
 4 = cannot stand   
Abbreviations: BOL, buccal-oral-lingual; LLE, left lower extremity; LUE, left upper extremity; RLE, right lower 
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Premanifest Huntington’s disease:  
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Abstract 
Introduction: Different oculomotor abnormalities have been reported to occur in 
premanifest Huntington’s disease. The aim of this study is to investigate which oculomotor 
items of the Unified Huntington’s Disease Rating Scale (UHDRS) are affected in 
premanifest individuals compared to healthy controls, and if CAG repeat length and age 
are correlated with oculomotor abnormalities in premanifest Huntington’s disease gene 
carriers. 
Methods: We compared baseline data of 70 premanifest individuals and 27 controls who 
participated in the Enroll-HD study at the Leiden University Medical Center, the 
Netherlands. Premanifest gene carriers were divided in individuals near to disease onset 
and individuals far from disease onset. 
Results: Using a logistic regression model, only horizontal ocular pursuit of the six 
oculomotor items of the UHDRS was significantly more frequently affected in premanifest 
individuals close to disease onset compared to controls (p = 0.044, OR 13.100). Age was 
significantly higher in premanifest individuals with affected horizontal ocular pursuit (p = 
0.016, OR 1.115) and with affected vertical ocular pursuit (p = 0.030, OR 1.065) compared 
to premanifest individuals without ocular pursuit deficits. 
Conclusions: Our results suggest that horizontal ocular pursuit is the only affected 
oculomotor item of the UHDRS in premanifest individuals and could be used to assess 
early clinical signs of Huntington’s disease. Saccade initiation and saccade velocity do not 
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Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder 
characterized by progressive motor, cognitive and psychiatric symptoms. It is caused by an 
expanded cytosine-adenine-guanine (CAG) trinucleotide repeat in the Huntingtin gene on 
chromosome 4.1 The mean age at onset is between 30 and 50 years, with a range of 2 to 
85 years.2 
Many studies have focused on the identification of potential biomarkers in premanifest 
HD. The standard clinical assessment tool for HD is the Unified Huntington’s Disease 
Rating Scale (UHDRS).3 The PREDICT-HD study showed that premanifest individuals closer 
to estimated age of disease onset had worse scores in the chorea, the bradykinesia, and 
the oculomotor domain of the UHDRS than individuals further from estimated diagnosis.4 
Several cross-sectional studies have shown that eye movements are impaired in an early 
stage of HD, often long before other symptoms become clinically relevant. These studies 
with eye-tracking equipment have found abnormal antisaccade and memory guided tasks, 
variability of latency, and error rates.5-8 However, eye-tracking equipment is not easily 
accessible in a clinical setting. Instead, the oculomotor items of the UHDRS are much 
easier to use in clinical practice. 
The aim of our study is to determine if the oculomotor items of the UHDRS show relevant 
abnormalities in premanifest HD. We also want to examine if a higher CAG expansion is 
associated with more oculomotor abnormalities in premanifest HD individuals compared 
to lower CAG expansions, considering CAG repeat length is inversely correlated with age 
of disease onset.9,10 Additionally, we aim to examine the relationship of age on 
oculomotor deficits in premanifest HD individuals, since oculomotor abnormalities also 
occur under the influence of ageing in healthy people.11,12 
 
Materials and methods 
Baseline data of subjects participating in the Enroll-HD study at the Leiden University 
Medical Center (LUMC), the Netherlands, were included in this study. Enroll-HD is an 
observational, prospective, international, multi-center study without experimental 
treatment. The Medical Ethics Committee of the LUMC approved the study (P13.167) and 
written informed consent was obtained from all participants. Assessments performed in 
this study include the examination of motor functioning using the UHDRS-Total Motor 
Score (TMS). Testing conditions were uniform across all subjects, and according to the 
instructions of the UHDRS-TMS teaching film.13 The oculomotor assessments were 
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performed before the other motor assessments. The UHDRS-TMS was performed by four 
different raters. The raters were not blinded to the status of the participants. The six 
oculomotor items of the UHDRS-TMS are horizontal and vertical ocular pursuit, horizontal 
and vertical saccade initiation, and horizontal and vertical saccade velocity (Table 1). They 
can all be rated from 0 ‘normal’ to 4 ‘cannot perform’. Overall, higher scores indicate 
more severe motor impairment. 
A total of 326 participants visited the neurology department of the LUMC for a baseline 
visit of Enroll-HD between October 2014 and September 2016. Manifest HD patients (n = 
220) and participants with an unknown genotype (n = 9) were excluded. Seventy 
premanifest HD individuals and 27 controls (genotype negative individuals (n = 14), family 
controls (n = 12) and community controls (n = 1)) were included. Premanifest gene carriers 
were defined as having a total motor score of 5 or less on the UHDRS-TMS. Premanifest 
HD gene carriers were divided in premanifest individuals near to disease onset and 
premanifest individuals far from disease onset by the group median for expected years to 
HD onset (13.7 years). Expected years to onset was calculated for each individual using the 
formula described by Langbehn et al.14, which is based on CAG repeat length and age at 
visit. Genotype negative individuals were potentially at risk for HD, but tested negative.
 
Table 1. The oculomotor items of the Unified Huntington's Disease Rating Scale 
Ocular pursuit 0 = complete (normal) 
(horizontal and vertical) 1 = jerky movement 
 2 = interrupted pursuit/full range 
 3 = incomplete range 
 4 = cannot pursue 
Saccade initiation 0 = normal 
(horizontal and vertical) 1 = increased latency only 
 2 = suppressible blinks or head movements to initiate 
 3 = unsuppressible head movements 
 4 = cannot initiate saccades 
Saccade velocity 0 = normal 
(horizontal and vertical) 1 = mild slowing 
 2 = moderate slowing 
 3 = severely slow, full range 
 4 = incomplete range 
 
35Oculomotor abnormalities in premanifest HD |
performed before the other motor assessments. The UHDRS-TMS was performed by four 
different raters. The raters were not blinded to the status of the participants. The six 
oculomotor items of the UHDRS-TMS are horizontal and vertical ocular pursuit, horizontal 
and vertical saccade initiation, and horizontal and vertical saccade velocity (Table 1). They 
can all be rated from 0 ‘normal’ to 4 ‘cannot perform’. Overall, higher scores indicate 
more severe motor impairment. 
A total of 326 participants visited the neurology department of the LUMC for a baseline 
visit of Enroll-HD between October 2014 and September 2016. Manifest HD patients (n = 
220) and participants with an unknown genotype (n = 9) were excluded. Seventy 
premanifest HD individuals and 27 controls (genotype negative individuals (n = 14), family 
controls (n = 12) and community controls (n = 1)) were included. Premanifest gene carriers 
were defined as having a total motor score of 5 or less on the UHDRS-TMS. Premanifest 
HD gene carriers were divided in premanifest individuals near to disease onset and 
premanifest individuals far from disease onset by the group median for expected years to 
HD onset (13.7 years). Expected years to onset was calculated for each individual using the 
formula described by Langbehn et al.14, which is based on CAG repeat length and age at 
visit. Genotype negative individuals were potentially at risk for HD, but tested negative.
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Ocular pursuit 0 = complete (normal) 
(horizontal and vertical) 1 = jerky movement 
 2 = interrupted pursuit/full range 
 3 = incomplete range 
 4 = cannot pursue 
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 2 = suppressible blinks or head movements to initiate 
 3 = unsuppressible head movements 
 4 = cannot initiate saccades 
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Family controls were non-related family members of HD gene carriers (mainly husbands 
and wives). The community control volunteered and did not visit the neurology 
department before. 
Statistical analysis was performed using IBM Statistical Package for the Social Sciences 
(SPSS) version 23. Demographics were calculated using independent sample t-tests and 
Chi-square tests. A linear regression analysis of the UHDRS-TMS as a function of age was 
performed among controls. Comparisons between premanifest individuals and controls 
for the six oculomotor items were performed using a logistic regression model, adjusting 
for age and gender. The UHDRS total oculomotor score is the sum of the separate 
oculomotor items and comparisons for this score between premanifest individuals and 
controls were assessed using a linear regression model, controlling for age and gender. 
The relationships between oculomotor abnormalities and CAG repeat length and age were 
calculated using a logistic regression model, controlling for gender. The oculomotor items 
served as dependent variables and CAG repeat length and age as independent variables. A 
p-value of <0.05 was considered statistically significant. 
 
Results 
Demographic data are shown in Table 2. Premanifest HD gene carriers were significantly 
younger (p < 0.001) than controls and had a lower UHDRS-TMS (p = 0.005). In the control 
group, UHDRS-TMS was not related to age (p = 0.271). CAG repeat length was available for 
a minority of the controls, because it was not determined in non-related family controls 
and community controls who were not at risk for HD. Premanifest individuals closer to 
disease onset were older (p = 0.002), had a higher CAG expansion (p < 0.001), and a higher 
UHDRS-TMS (p = 0.015) compared to premanifest HD gene carriers further from disease 
onset. 
All subjects scored 0 ‘normal’ or 1 ‘mild abnormality’ on the six oculomotor items of the 
UHDRS, and were therefore classified as ‘not affected’ or ‘affected’ respectively. Of the six 
oculomotor items, vertical ocular pursuit was the most frequently affected item in 
premanifest individuals (32.9%) as well as in controls (22.2%) (Table 3). Horizontal saccade 
velocity was not affected once in the entire group. When comparing all premanifest gene 
carriers to controls no statistically significant differences were found for the total UHDRS 
oculomotor score, or any of the six separate oculomotor items. However, when 
premanifest HD individuals near to disease onset were compared with healthy controls a 
significant difference was seen for horizontal ocular pursuit (p = 0.044, OR 13.100), with 
more premanifest individuals affected than controls. A similar trend was observed for 




































































































































































































































































































































































































































































































































































































































































     


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































vertical ocular pursuit (p = 0.075, OR 2.967). Horizontal and vertical saccade initiation, and 
horizontal and vertical saccade velocity did not show any differences between the groups. 
The relationship between the oculomotor items of the UHDRS and CAG repeat length and 
age was examined in premanifest individuals, controlling for gender. CAG repeat length 
was not related to horizontal and vertical ocular pursuit (Table 4). Age was significantly 
higher in the affected horizontal ocular pursuit group (p = 0.016, OR 1.115) and the 
affected vertical ocular pursuit group (p = 0.030, OR 1.065) compared to premanifest 
individuals without ocular pursuit deficits. 
 
Discussion 
In this cross-sectional study we showed that only horizontal ocular pursuit of the UHDRS 
oculomotor domain is affected in premanifest individuals near to HD onset compared to 
healthy controls. This is not the case when all premanifest HD gene carriers are compared 
with controls. This suggests that horizontal ocular pursuit is the only affected item of the 
six oculomotor items of the UHDRS in premanifest individuals. Vertical ocular pursuit 
showed a tendency towards the same. 
Our demographic data showed that premanifest individuals near to HD onset were older, 
had a higher CAG expansion, and a higher UHDRS-TMS compared to premanifest HD gene 
carriers far from HD onset. These findings were expected, since age and CAG repeat length 
were used to calculate the expected years to HD onset according to the Langbehn 
formula.14 The higher UHDRS-TMS found in controls compared to premanifest individuals 
is probably due to the higher age of the participants in this group, which has been 
reported before.15 However, a linear regression analysis of the UHDRS-TMS as a function 
of age among controls did not show this correlation. 
To our knowledge no study has been performed investigating the separate items of the 
oculomotor domain of the UHDRS in premanifest HD individuals and controls. Other cross-
sectional reports using clinical oculomotor assessments only showed that premanifest 
individuals performed significantly worse compared to controls on the total score of the 
oculomotor domain of the UHDRS,4 and on the overall oculomotor function, saccade 
velocity, and optokinetic nystagmus of the Quantified Neurologic Examination.16 Our study 
did not find a difference for the total UHDRS oculomotor score between controls and 
premanifest individuals. This could be caused by a different definition used for 
premanifest HD individuals, which caused lower total oculomotor scores on the UHDRS-
TMS in our study. Biglan et al.4 used a diagnostic confidence level to identify premanifest 
individuals. As a result, individuals with an UHDRS-TMS higher than 5 were often defined 
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as premanifest, because participants were only defined as manifest when the examiner 
was more than 98 percent confident the participant had signs of HD. Accordingly, patients 
with a relatively high UHDRS-TMS were categorized as premanifest rather than manifest, 
while those same patients would have been categorized as manifest in our study. Our 
study’s definition of premanifest HD, therefore, selects for lower UHDRS-TMS scores and, 
accordingly, the UHDRS total oculomotor scores were also lower in premanifest HD gene 
carriers in our study. 
Differences found between controls and premanifest HD gene carriers are important, 
because they increase knowledge about early disease progression, and possibly indicate 
the first clinical signs present in premanifest HD. Since eye-tracking equipment is not 
practical in everyday clinical practice, it is relevant to know if the oculomotor items of the 
UHDRS are useful to detect early HD signs in patients. Our results suggest that horizontal 
ocular pursuit is the only affected oculomotor item in premanifest individuals and could 
be used to assess early clinical signs of HD in individuals who are at risk for developing HD. 
Vertical ocular pursuit was not significantly different between premanifest individuals 
close to disease onset and controls, but a trend was seen for this item as well. Horizontal 
and vertical saccade initiation, and horizontal and vertical saccade velocity did not show 
any differences between premanifest individuals and controls or between premanifest 
individuals close to disease onset and controls. Therefore these items of the UHDRS do 
not seem to contribute in detecting early disease signs. The fact that we did not find 
significant differences does not necessarily mean that they are not present, but might 
show that these items are not sensitive enough to defect deficits. Siesling et al.17 also 
questioned the importance of the eye movements, because omitting saccade initiation 
and saccade velocity from the UHDRS-TMS only led to a small loss in correlation between 
the other items. 
In contrast, other studies did find differences between premanifest individuals and 
controls for saccade initiation and saccade velocity.5-8 However, these studies used eye-
tracking equipment. They reported oculomotor abnormalities between premanifest HD 
gene carriers and controls, which consisted of more complex antisaccade and memory 
guided tasks, variability of latency, and error rates. However, in the TRACK-HD study,18 
antisaccade error rates in controls did not differ from those in premanifest individuals, 
only from those in premanifest individuals closer to predicted HD onset. Eye-tracking 
equipment did not show significant differences for horizontal and vertical pursuit tracking 
between premanifest individuals and controls.5 Only one study compared results from 
eye-tracking equipment with clinical ratings of the UHDRS oculomotor section. Saccade 
initiation of the UHDRS was correlated with the average latency of saccades measured 
with the eye-tracking system. The correlation between the saccade velocity of the UHDRS 
and the measured velocity was not significant.6 
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not seem to contribute in detecting early disease signs. The fact that we did not find 
significant differences does not necessarily mean that they are not present, but might 
show that these items are not sensitive enough to defect deficits. Siesling et al.17 also 
questioned the importance of the eye movements, because omitting saccade initiation 
and saccade velocity from the UHDRS-TMS only led to a small loss in correlation between 
the other items. 
In contrast, other studies did find differences between premanifest individuals and 
controls for saccade initiation and saccade velocity.5-8 However, these studies used eye-
tracking equipment. They reported oculomotor abnormalities between premanifest HD 
gene carriers and controls, which consisted of more complex antisaccade and memory 
guided tasks, variability of latency, and error rates. However, in the TRACK-HD study,18 
antisaccade error rates in controls did not differ from those in premanifest individuals, 
only from those in premanifest individuals closer to predicted HD onset. Eye-tracking 
equipment did not show significant differences for horizontal and vertical pursuit tracking 
between premanifest individuals and controls.5 Only one study compared results from 
eye-tracking equipment with clinical ratings of the UHDRS oculomotor section. Saccade 
initiation of the UHDRS was correlated with the average latency of saccades measured 
with the eye-tracking system. The correlation between the saccade velocity of the UHDRS 
and the measured velocity was not significant.6 
 
In the second part of our study we examined the relationship between CAG repeat length 
and oculomotor abnormalities, and age and oculomotor abnormalities in premanifest HD 
individuals. Because saccade initiation and saccade velocity did not show differences 
between premanifest individuals and controls, we only examined ocular pursuit. We did 
not find a relationship between CAG repeat length and ocular pursuit. Age, however, was 
related to both horizontal and vertical ocular pursuit. This suggests that a clinician should 
be more aware of the possibility of affected ocular pursuit in older premanifest HD gene 
carriers. Especially since older individuals are more likely to be closer to HD onset. 
A limitation of our study is the relatively small sample size and therefore the small number 
of participants who had oculomotor abnormalities. Secondly, the examiners were not 
blinded to the status of the participants. As a result, equivocal findings may have been 
graded as abnormal in premanifest HD gene carriers and normal in controls, thereby 
biasing results against the null hypothesis. Clinical examination of the oculomotor items of 
the UHDRS has its limitations due to difficulty in distinguishing between subtle possible 
pathology and normal eye movements, and due to interrater reliability. Previous studies 
have shown that the interrater reliability of the total UHDRS motor score is high, however 
they did not report the interrater reliability of the UHDRS oculomotor domain.3,19 
Additionally, eye movement abnormalities can have a nonspecific nature as well. 
Furthermore, we have tested multiple hypothesis without accounting for multiple 
comparisons. We did not correct for multiple comparisons because of the relatively small 
sample size and the likely presence of correlations between the different items. 
Accordingly, significant findings may be due to chance alone. If we want to decide 
whether or not the UHDRS oculomotor domain is as good as eye-tracking equipment to 
determine oculomotor abnormalities, these two assessments should be assessed together 
in an observational, prospective study. 
 
Conclusions 
In conclusion, we found that significantly more premanifest HD individuals near to disease 
onset had affected horizontal ocular pursuit compared to controls. This suggests that 
horizontal ocular pursuit is the only affected oculomotor item in premanifest individuals 
and could be used to assess early clinical signs of HD. Saccade initiation and saccade 
velocity do not seem useful for detecting differences between premanifest individuals and 
healthy controls. Therefore, when assessing individuals at risk for HD, these items of the 
UHDRS-TMS might be omitted. Our results also showed that higher age is related to 
horizontal and vertical ocular pursuit deficits in premanifest individuals. CAG repeat length 
was not related to oculomotor abnormalities. 
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Abstract 
Background: The standard clinical assessment tool in Huntington’s disease is the Unified 
Huntington’s Disease Rating Scale (UHDRS). In patients with advanced Huntington’s 
disease ceiling and floor effects of the UHDRS hamper the detection of changes. 
Therefore, the UHDRS-For Advanced Patients (UHDRS-FAP) has been designed for patients 
with late stage Huntington’s disease. 
Objectives: This cross-sectional study aims to examine if the UHDRS-FAP can differentiate 
better between patients with advanced Huntington’s disease than the UHDRS. 
Methods: Forty patients, who were institutionalized or received day-care, were assessed 
with the UHDRS, UHDRS-FAP, and Care Dependency Scale (CDS). The severity of 
Huntington’s disease was defined by the Total Functional Capacity (TFC). Comparisons 
between consecutive TFC stages were performed for all domains of the UHDRS, UHDRS-
FAP, and CDS using Mann-Whitney U tests. 
Results: The motor scores of the UHDRS-FAP and UHDRS were the only subscales with 
significantly worse scores in TFC stage 5 compared to stage 4. In TFC stages 4-5, the range 
of the UHDRS-FAP motor score was broader, the standard error of measurement was 
lower, and the effect size r was higher than for the UHDRS motor score. The CDS declined 
significantly across all TFC stages. 
Conclusions: Our results suggest that the UHDRS-FAP motor score might differentiate 
better between patients with severe Huntington’s disease than the UHDRS motor score. 
Therefore, the UHDRS-FAP motor score is potentially a better instrument than the UHDRS 
motor score to improve disease monitoring and, subsequently, care in patients with 
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Huntington’s disease (HD) is an autosomal dominant, progressive neurodegenerative 
disorder caused by an expanded cytosine-adenine-guanine (CAG) trinucleotide repeat in 
the Huntingtin gene on chromosome 4.1 The disease is clinically characterized by disorders 
of movement, cognition, and behavior. Progression of HD into more advanced stages 
ultimately leads to functional decline. The mean age at disease onset is between 30 and 
50 years and the mean duration of HD is 17 to 20 years.2 
The standard clinical assessment tool in HD is the Unified Huntington’s Disease Rating 
Scale (UHDRS).3 The UHDRS has been developed to monitor disease progression in 
individual patients, and is used in research and in clinical practice. The UHDRS has 
demonstrated to be sensitive to detect longitudinal changes in manifest HD patients.3-8 
In more advanced stages of HD, knowledge is limited about the course of the clinical 
manifestations. There is a lack of sensitive disease outcome measures to track disease 
progression and guidelines for symptom management in late stage care.9 Ceiling and floor 
effects of the UHDRS hamper the detection of changes in patients with advanced HD.8 This 
limitation makes disease monitoring difficult and complicates the measurement of effect 
of therapeutic interventions in advanced HD. Therefore, the UHDRS-For Advanced 
Patients (UHDRS-FAP) has been designed for patients with late stage HD.10 The authors 
showed that both the UHDRS and the UHDRS-FAP detected a decline in patients with 
advanced HD. However, the UHDRS-FAP appeared to be more sensitive to change and was 
the only scale that detected a decline in patients with a very low functional capacity.10 
Although the UHDRS-FAP was shown to be more sensitive to detect decline than the 
UHDRS when assessed longitudinally in patients with advanced HD, it is not implemented 
yet on a larger scale in long-term care facilities and little is known about its cross-sectional 
properties. Therefore, we aim to explore its capacity to differentiate between the later 
stages of the disease on the basis of cross-sectional data in one long-term care facility. We 
also aim to confirm previous findings about the internal consistency and interrater 









Participants and setting 
All patients (n = 90) with a clinically and/or genetically confirmed diagnosis of HD, who 
were institutionalized or received day-care at the Huntington Center Topaz Overduin 
(Katwijk), were asked to participate in this study. Patients had to be older than 18 years of 
age. Exclusion criteria were a central nervous system disorder other than HD and 
participation in an interventional medical trial during the study. Forty patients were able 
and willing to participate. The local medical ethics committee approved the study and 
written informed consent was obtained from all participants or their caregivers. 
Huntington Center Topaz Overduin is a nursing home specialized in the care for HD 
patients, both in late and early stages, with 70 beds and over 100 outpatients. Specialized 
medical doctors, psychologists, therapists, and nursing personnel provide long-term care 
and day-care in the nursing home, organize activities, and offer support for patients who 
live at home. This study was carried out in 2017. On the same day, patients were first 
assessed with the UHDRS followed by the UHDRS-FAP. Both scales were administered 
twice by two independent medical doctors experienced with HD with an intended interval 
of seven days. 
 
Assessments 
The UHDRS is divided into four domains: motor performance, cognitive function, 
behavioral abnormalities, and functional abilities.3 The motor section consists of 31 items 
assessing oculomotor, bradykinesia/rigidity, dystonia, chorea, and gait/balance.3 The 
items are rated from zero to four, with zero indicating normal findings and four indicating 
severe abnormalities. The range of the Total Motor Score (TMS) is 0 to 124, with higher 
scores indicating more severe motor impairment. The cognitive component includes the 
Verbal Fluency test,11 the Symbol Digit Modalities test,12 and the Stroop test (color 
naming, word reading, and interference).13 Lower scores indicate worse cognitive 
performance. The behavioral assessment measures the frequency and severity of 11 
items, which are rated from zero (almost never/absent) to four (almost always/severe).3 
The items assess depression, anxiety, aggression, psychosis, and other behavioral 
abnormalities. The behavioral score ranges from 0 to 88, with higher scores indicating 
more severe psychiatric abnormalities. The functional domain comprises three 
components, namely the Total Functional Capacity (TFC), the Functional Assessment Scale 
(FAS), and the Independence Scale (IS).3 The TFC consists of five items (occupation, 
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(FAS), and the Independence Scale (IS).3 The TFC consists of five items (occupation, 
 
finances, domestic chores, activities of daily living, and care level) and ranges from 0 to 
13.14 The FAS includes 25 yes/no questions about common daily tasks (range 0-25). The IS 
measures the level of independence by one single score between 10 and 100. For all 
functional scores, lower scores indicate a worse function. 
The UHDRS-FAP consists of four sections, which are the motor, cognitive, somatic, and 
behavioral sections.10 The motor domain comprises 14 items assessing frequency of 
falling, dysphagia, muscle contractures, and the capacity to eat, dress, and wash 
independently, as well as other motor components (range 0-52). Cognitive function is 
measured by functional and categorical matching of the Protocole Toulouse Montreal 
d’Evaluation des Gnosies Visuelles (PEGV),15 pointing, simple commands, the Stroop test, 
orientation, participation in activities, imitation (apraxia), and automatic series. The 
somatic subscale includes ten items assessing hyperhidrosis, hypersalivation, 
incontinence, digestion, hypersomnia, and pressure ulcers (range 0-28). The behavioral 
score consists of eight yes/no questions about the presence of psychiatric abnormalities 
(range 0-8). For the motor, somatic, and behavioral section, higher scores indicate more 
impairment, and for the cognitive section, lower scores indicate worse performance. 
Nurses directly involved in patient care completed the Care Dependency Scale (CDS).16 The 
CDS is a questionnaire of 15 items assessing different aspects of dependency on care in 
daily activities (eating and drinking, incontinence, mobility, communication, and other 
care items). The total CDS score ranges from 15 (completely dependent on care) to 75 
(almost independent of care). 
 
Statistical analysis 
IBM Statistical Package for the Social Sciences (SPSS) version 23 was used for data analysis. 
Internal consistency was assessed in all subscales of the UHDRS and the UHDRS-FAP for all 
first evaluations using Cronbach’s alpha (α). Interrater reliability of each section of both 
scales was calculated by the intraclass correlation coefficient (ICC). We used a two-way 
random model with absolute agreement. The motor, cognitive, and behavioral sections of 
the UHDRS-FAP were compared with the motor, cognitive, and behavioral sections of the 
UHDRS using Spearman’s rank correlation coefficients (ρ). Again, we used the scores of all 
first evaluations. An ICC, Cronbach’s α, or ρ higher than 0.7 was considered good and 
lower than 0.4 was defined as poor.17,18 Severity of HD was divided into five stages using 
the TFC subscale of the UHDRS: stage 1 (TFC 11-13), stage 2 (TFC 7-10), stage 3 (TFC 3-6), 
stage 4 (TFC 1-2), and stage 5 (TFC 0).14 A higher TFC stage indicates worse functional 
capacity. The participants were classified according to their TFC stage and the median 
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scores of each section of the UHDRS, UHDRS-FAP, and CDS were calculated per stage. 
Comparisons of the UHDRS and UHDRS-FAP domains and the CDS were performed across 
the different TFC stages using Mann-Whitney U tests. For all comparisons, we used the 
scores of the first evaluations. A p-value of <0.05 was considered statistically significant. 
For the higher TFC stages, we also calculated the effect size (r), the range and the standard 
error of measurement (SEM) of the motor section of both scales to examine which scale 
differentiates better in more advanced HD. A higher r, broader range, and lower SEM 
suggested a better differentiation between patients. 
 
Results 
Forty patients with advanced HD participated in this study. Age and gender of study 
participants were similar to the age and gender of the patients who did not consent to 
participate in the study. In the nursing home unit specialized in psychiatric problems and 
the unit with patients highly dependent on care, less patients chose to participate in the 
study (35% and 31%, respectively) than in the unit with patients less dependent on care 
and the day-care department (57% and 60%, respectively). Participants were assessed 
twice by two independent raters. Time between the two evaluations was 7 to 23 days 
(median of seven days). The second time 37 patients participated; two patients found the 
assessments too confrontational and one had died. Demographic data of the 40 
participants are reported in Table 1. CAG repeat length was missing for two patients, 
because they were tested for HD through linkage analysis before the identification of the 
Huntingtin gene in 1993. Medication for HD symptoms, such as antidepressants, 
antipsychotics, tetrabenazine, and benzodiazepines, was used by 95% of the patients. 
Medication was stable between the two evaluations. Mean scores of the separate sections 
of the UHDRS and UHDRS-FAP are reported in Table 2. 
Internal consistency was high for the motor score (α = 0.966), cognitive score (α = 0.937), 
and FAS (α = 0.945) of the UHDRS and for the motor score (α = 0.902) and cognitive score 
(α = 0.857) of the UHDRS-FAP (Table 3). The behavorial score of the UHDRS-FAP had a low 
internal consistency (α = 0.347). Interrater reliability was calculated for the two raters who 
examined both 37 HD patients. Moderate ICC values were found for the behavioral score 
of both the UHDRS and UHDRS-FAP (0.681 and 0.503, respectively; Table 3). ICC values 
were high for all other subscales of the UHDRS and UHDRS-FAP. Interrater reliability of the 
UHDRS-FAP motor score (ICC = 0.954) was higher than for the UHDRS-TMS (ICC = 0.876). 
The motor, cognitive, and behavioral domains of the UHDRS-FAP correlated strongly with 
the corresponding domains of the UHDRS (ρ = 0.860, ρ = 0.991, and ρ = 0.714, 
respectively). 
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the corresponding domains of the UHDRS (ρ = 0.860, ρ = 0.991, and ρ = 0.714, 
respectively). 
 
Table 1. Demographic data of all participants (n = 40) 
Age, years 54.5 (±12.8) 
Male/female (% male) 14/26 (35.0%) 
CAG repeat length (n = 38) 44.8 (±3.8) 
Educational level, years 13.3 (±2.9) 
Age of disease onset, years 40.7 (±11.3) 
Disease duration, years 13.4 (±5.1) 
Nursing home/day-care (% nursing home) 28/12 (70.0%) 
Data are mean (± standard deviation) for age, CAG repeat length, educational level, age of disease onset and 
disease duration, and number (%) for male/female and nursing home/day-care. 
 




Mean (SD) Min-Max Mean (SD) Min-Max 
Motor score 64.2 (±26.1) 0-124 14.9 (±11.3) 0-52 
Cognitive score 78.1 (±64.6) 0-∞ 109.8 (±65.4) 0-∞ 
Behavioral score 15.5 (±8.9) 0-88 1.8 (±1.4) 0-8 
Somatic score 
  
6.9 (±6.0) 0-28 
Total Functional Capacity 2.6 (±2.3) 0-13 
  Functional Assessment Scale 9.6 (±6.7) 0-25 
  Independence Scale 55.5 (±16.9) 10-100 
  Mean scores are given for all sections of the UHDRS and UHDRS-FAP. 
Abbreviations: Max, maximum; Min, minimum; SD, standard deviation; UHDRS, Unified Huntington's Disease 
Rating Scale; UHDRS-FAP, Unified Huntington's Disease Rating Scale-For Advanced Patients. 
 
Median scores of the UHDRS and UHDRS-FAP sections and the CDS for the different TFC 
stages are shown in Table 4. The UHDRS-TMS was significantly different between all 
consecutive TFC stages, while the motor score of the UHDRS-FAP was only significantly 
different between TFC stages 3 and 4 (p < 0.001), and between TFC stages 4 and 5 (p = 
0.019; i.e., the scores were significantly worse in patients with more advanced HD). In TFC 
stages 4 and 5, the effect size r was higher for the UHDRS-FAP motor score compared to 
the UHDRS-TMS (0.525 and 0.466, respectively). The proportion of the range of the 
UHDRS-FAP motor score that was covered was broader than for the UHDRS-TMS (17.9% 
and 8.9%, respectively), and the SEM was lower (1.89 and 5.63, respectively) in TFC stages 
4 and 5. The cognitive section of both scales was only significantly different between TFC 
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Figure 1. Z-scores of the motor, cognitive, behavioral, and somatic scores of the Unified Huntington’s Disease 
Rating Scale (UHDRS; light grey) and the Unified Huntington’s Disease Rating Scale-For Advanced Patients 
(UHDRS-FAP; dark grey) across the Total Functional Capacity (TFC) stages. 
 
stages 3 and 4. The behavioral score of both the UHDRS and UHDRS-FAP and the somatic 
score did not show any differences between the TFC stages. The CDS declined significantly 
across all TFC stages. Z-scores of the motor, cognitive, behavioral, and somatic scores of 
the UHDRS and UHDRS-FAP across the TFC stages are also presented in Fig 1. 
 
Discussion 
This study in advanced HD patients demonstrated that the UHDRS-FAP motor score and 
the UHDRS-TMS were the only subscales with a significantly worse score in TFC stage 5 
compared to stage 4. The scores of the other UHDRS-FAP and UHDRS sections did not 
differ between TFC stages 4 and 5, suggesting that the UHDRS-FAP motor score and the 
UHDRS-TMS are the only subscales that can differentiate between patients in high TFC 
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stages. However, in TFC stages 4 and 5, the range of the UHDRS-FAP motor score was 
broader, the SEM was lower, and the effect size r was higher than for the UHDRS-TMS. 
These findings suggest that the motor score of the UHDRS-FAP might differentiate better 
between patients with advanced HD than the UHDRS-TMS. Therefore, this scale could 
avoid the ceiling effect sometimes seen in the UHDRS-TMS and subsequently, prove more 
beneficial in research and clinical care of patients with very advanced HD. Furthermore, 
implementation of the UHDRS-FAP motor score in daily practice could improve disease 
monitoring and, therefore, care in patients with advanced HD residing in long-term care 
facilities. In particular, when a new patient is admitted to a nursing home, this score can 
serve as a screening instrument and provide information about motor performance and 
care needed. The motor score of the UHDRS-FAP can easily be administered in nursing 
homes and only takes a few minutes to complete. Multiple longitudinal studies have 
reported an increase of the UHDRS-TMS during follow-up. However, these studies did not 
differentiate between different TFC stages, and the patients were in a less advanced HD 
stage.3-6 Another study, in which a longitudinal assessment of the UHDRS-FAP and UHDRS 
was performed, showed an increase of the motor score in both scales over time, with a 
steeper slope for the UHDRS-FAP than for the UHDRS.10 Moreover, in patients with TFC 
scores ≤ 1, only the UHDRS-FAP motor score deteriorated, whereas the UHDRS-TMS did 
not, confirming the UHDRS-TMS ceiling effect in advanced HD. 
We showed that the cognitive score of the UHDRS and UHDRS-FAP differed significantly 
between TFC stages 3 and 4, but not between TFC stages 4 and 5. This finding suggests 
that the cognitive domain of both scales is informative in the middle stages of HD, but not 
in the late stages. Therefore, the usefulness of assessment of cognition in very advanced 
HD should be questioned. A longitudinal study on cognitive performance across the TFC 
stages showed that the cognitive tests of the UHDRS declined significantly in consecutive 
TFC stages, except from TFC stage 4 to 5.19 This also implies that cognitive assessment is 
not useful in late stage HD, or at least the scale is not sensitive enough to detect 
differences. Youssov et al. also reported that the cognitive section of the UHDRS did not 
decline over time in patients with low functional capacity (TFC scores ≤ 1). However, the 
cognitive section of the UHDRS-FAP did decline when assessed longitudinally.10 
The behavioral section of the UHDRS and UHDRS-FAP did not differ between any of the 
consecutive TFC stages in our study, suggesting that behavioral abnormalities do not 
progress when HD becomes more severe. However, this could be caused partly by less 
communicative abilities of patients in late stage HD. Studies of the Problem Behaviors 
Assessment (PBA), an adjusted version of the UHDRS behavioral section, showed that only 
apathy is related to disease duration.20,21 Depression and irritability were not related to 
disease stage. Several studies found that the UHDRS behavioral section did not correlate 
with the other sections of the UHDRS,3,10,22 which also suggests that psychiatric 
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abnormalities do not progress across the disease stages. Furthermore, longitudinal 
assessment of the behavioral domain of the UHDRS and UHDRS-FAP did not show 
deterioration over time.4-6,10 Only in a subgroup of HD patients did the UHDRS-FAP 
behavioral score worsen over time.10 The results of our study suggest that the behavioral 
sections of the UHDRS and UHDRS-FAP are not useful to differentiate between the TFC 
stages. However, for clinical care an estimation of a patient’s behavioral disturbances is 
relevant and, therefore, the behavioral section is useful for clinical care. 
The CDS is completed by nursing personnel and has previously been validated in patients 
with dementia in long-term care facilities. Our study in HD patients showed a similar mean 
score (HD: 47.9, dementia: men 47.5, women 43.0) and internal consistency (HD: 
Cronbach’s α = 0.961, dementia: Cronbach’s α = 0.97) for the CDS as in patients with 
dementia.16,23 This suggests that the CDS could also be applied in the care for HD patients 
in nursing homes. 
We found a high internal consistency for the motor score, cognitive score, and FAS of the 
UHDRS and for the motor score and cognitive score of the UHDRS-FAP, which confirmed 
previous findings.3,10 The behavorial score of the UHDRS-FAP had a low internal 
consistency (Cronbach’s α = 0.347), which is far below the generally accepted value for use 
in research (0.7).17,18 A previous study on the UHDRS-FAP also reported that the internal 
consistency of the UHDRS-FAP behavioral score (Cronbach’s α = 0.49) was lower than that 
of the UHDRS-FAP motor and cognitive score.10 The low internal consistency might be 
explained by the fact that the behavioral score of the UHDRS-FAP only consists of eight 
yes/no questions. Interrater reliability was high for all subscales of the UHDRS and UHDRS-
FAP, except for the behavioral subscales. Several studies found similar ICC values for the 
motor and cognitive domains of the UHDRS and UHDRS-FAP.3,10 However, due to the day 
to day variation of signs within a patient, the time between the two examinations by the 
two raters (median of seven days) may have affected the interrater reliability in our study. 
Furthermore, the short retest interval may have influenced the cognitive performance the 
second time and therewith the interrater reliability due to a possible learning effect.24,25 
Moderate ICC values were found for the behavioral subscale of both the UHDRS and 
UHDRS-FAP (0.681 and 0.503, respectively). This contradicts previous studies, which found 
high interrater reliability (0.73-0.99).10,20,21 However, two of these previous studies used 
the PBA instead of the UHDRS behavioral section and calculated a “clinically relevant” 
interrater reliability, which means only differences larger than one point were 
included.20,21 As expected, we found high correlations between the motor, cognitive, and 
behavioral domain of the UHDRS and the UHDRS-FAP. 
The strengths of our study are the administration of both the UHDRS and UHDRS-FAP on 
the same day, so there is no variation within a patient, and that both raters received 
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training to perform the UHDRS. A limitation of this study is that due to practical reasons, 
the first assessment was not consistently performed by the same medical doctor, which 
may have caused variability in the outcome of the UHDRS and UHDRS-FAP scores. Each 
medical doctor examined about half of the patients first. Another limitation is the small 
sample size, especially in TFC stage 2. However, patients in this TFC stage are usually not 
classified as advanced. Additionally, our study reports only cross-sectional results. 
Longitudinal assessment of the UHDRS-FAP is necessary to examine if the scale is sensitive 
enough to detect changes within patients over time. 
In conclusion, in patients with advanced HD, the UHDRS-FAP motor score can be used to 
differentiate between patients in TFC stages 4 and 5. Therefore, this subscale can possibly 
improve disease monitoring and, subsequently, care in patients with advanced HD in long-
term care facilities. Cognitive and behavioral assessments do not seem useful for 
differentiating between patients in late stage HD (TFC stages 4 and 5). However, 
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CHAPTER 5  
Longitudinal assessment of the  
Unified Huntington’s Disease Rating Scale  
(UHDRS) and UHDRS-For Advanced Patients  
(UHDRS-FAP) in patients with late stage  
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Abstract 
Background and purpose: Symptoms and signs in patients with Huntington’s disease are 
usually assessed with the Unified Huntington’s Disease Rating Scale (UHDRS). Ceiling and 
floor effects hamper the measurement of disease progression in patients with late stage 
Huntington’s disease and therefore the UHDRS-For Advanced Patients (UHDRS-FAP) has 
been developed. The aim of this longitudinal study is to examine if the UHDRS-FAP and 
UHDRS are sensitive enough to detect change over time in late stage Huntington’s disease. 
Methods: Forty nursing home residents and patients receiving day-care were assessed 
with the UHDRS, UHDRS-FAP, and Care Dependency Scale (CDS). After six months, the 
assessment scales were completed again in 29 patients. Changes between baseline and 
follow-up were calculated using paired t-tests. Wilcoxon signed-rank tests were used to 
calculate longitudinal changes for middle and late stage patients separately. 
Results: The motor and cognitive score of the UHDRS-FAP deteriorated during six months’ 
follow-up, whilst the motor and cognitive score of the UHDRS did not show change. Two 
functional domains of the UHDRS and the CDS also declined. The behavioral score 
significantly improved with both rating scales in late stage patients. 
Conclusions: Our results suggest that the UHDRS-FAP motor and cognitive score, the 
functional domains of the UHDRS, and the CDS can detect disease progression in late 
stage Huntington’s disease. Therefore, the use of these scores in nursing homes is 
recommended to optimize care by monitoring disease progression and by evaluating the 










63 Longitudinal assessment in late stage HD |
 
Abstract 
Background and purpose: Symptoms and signs in patients with Huntington’s disease are 
usually assessed with the Unified Huntington’s Disease Rating Scale (UHDRS). Ceiling and 
floor effects hamper the measurement of disease progression in patients with late stage 
Huntington’s disease and therefore the UHDRS-For Advanced Patients (UHDRS-FAP) has 
been developed. The aim of this longitudinal study is to examine if the UHDRS-FAP and 
UHDRS are sensitive enough to detect change over time in late stage Huntington’s disease. 
Methods: Forty nursing home residents and patients receiving day-care were assessed 
with the UHDRS, UHDRS-FAP, and Care Dependency Scale (CDS). After six months, the 
assessment scales were completed again in 29 patients. Changes between baseline and 
follow-up were calculated using paired t-tests. Wilcoxon signed-rank tests were used to 
calculate longitudinal changes for middle and late stage patients separately. 
Results: The motor and cognitive score of the UHDRS-FAP deteriorated during six months’ 
follow-up, whilst the motor and cognitive score of the UHDRS did not show change. Two 
functional domains of the UHDRS and the CDS also declined. The behavioral score 
significantly improved with both rating scales in late stage patients. 
Conclusions: Our results suggest that the UHDRS-FAP motor and cognitive score, the 
functional domains of the UHDRS, and the CDS can detect disease progression in late 
stage Huntington’s disease. Therefore, the use of these scores in nursing homes is 
recommended to optimize care by monitoring disease progression and by evaluating the 












Huntington’s disease (HD) is a neurodegenerative disorder characterized by progressive 
motor impairment, cognitive decline, and psychiatric symptoms. It is caused by an 
autosomal dominantly inherited cytosine-adenine-guanine (CAG) trinucleotide repeat 
expansion in the Huntingtin gene on chromosome 4.1 HD usually becomes manifest 
around the age of 30-50 years and mean disease duration is 17-20 years.2 As the disease 
progresses, the symptoms lead to functional decline and loss of independency, which may 
require nursing home admission. 
Presence, severity and progression of symptoms and signs in HD patients are usually 
assessed with the Unified Huntington’s Disease Rating Scale (UHDRS), which is subdivided 
into motor, cognitive, behavioral and functional domains.3 Several studies have shown 
that the motor, cognitive and functional sections of the UHDRS can detect longitudinal 
changes in manifest HD patients.3-8 However, in late stage HD ceiling and floor effects of 
the UHDRS hamper the detection of changes8,9 and therefore disease progression is 
challenging to measure in patients with advanced HD, both in clinical practice and in 
research. For patients with late stage HD the UHDRS-For Advanced Patients (UHDRS-FAP) 
has been developed, which consists of motor, cognitive, somatic and behavioral 
sections.10 The developers of the scale have performed a longitudinal study of the UHDRS-
FAP, which showed that the motor, cognitive and somatic scores deteriorated over time.10 
The behavioral score only worsened in a subgroup of HD patients. 
Recently, our cross-sectional study concerning the sensitivity of the UHDRS and UHDRS-
FAP in patients with advanced HD showed that only the motor scores of the UHDRS and 
UHDRS-FAP could differentiate between patients with very low functional capacity.11 The 
cognitive, behavioral and somatic subscales did not differ between patients with low 
functional abilities. With this follow-up study, the aim is to examine if the UHDRS-FAP and 




Participants and setting 
Nursing home residents and patients receiving day-care at the Huntington Center Topaz 
Overduin (Katwijk, the Netherlands) were invited to participate in this study. The 
Huntington Center Topaz Overduin is specialized in care for HD patients and comprises a 
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nursing home with 70 residents, a day-care facility with 20 patients, and an outpatient 
clinic with over 100 patients. Inclusion criteria were a clinically and/or genetically 
confirmed diagnosis of HD and age above 18 years. Exclusion criteria comprised a central 
nervous system disorder other than HD or current participation in an interventional 
medical trial. The medical ethics committee of the Leiden University Medical Center 
approved the study and written informed consent was obtained from all participants or 
their caregivers. The participants were first assessed with the UHDRS followed by the 
UHDRS-FAP on the same day. Preferably, the caregivers of the patients were present 
when the scales were assessed. After six months both scales were completed again. The 
rating scales were administered by two medical doctors, who were both UHDRS certified. 




The motor section of the UHDRS, which is also called the UHDRS-Total Motor Score 
(UHDRS-TMS), is composed of 31 items ranging from 0 (not affected) to 4 (severely 
affected).3 Oculomotor function, bradykinesia/rigidity, chorea, dystonia, and gait/balance 
are examined. The UHDRS-TMS ranges from 0 to 124, with higher scores indicating worse 
motor performance. Cognitive function is tested with the Verbal Fluency test, the Symbol 
Digit Modalities test, and the Stroop test (color naming, word reading, and interference). 
Lower scores indicate worse cognitive function. Behavioral abnormalities are assessed by 
11 items, such as depression, anxiety, irritability/aggression, obsessive-compulsive 
behaviors, psychosis and apathy. Each item is rated for severity and frequency from 0 to 4 
and the range of the total score is 0-88, with higher scores indicating more severe 
psychiatric symptoms. Functional ability is measured by three subsections: Total 
Functional Capacity (TFC), the Functional Assessment Scale (FAS), and the Independence 
Scale (IS). TFC is a 5-item questionnaire concerning occupation, handling finances, 
domestic chores, activities of daily living and level of care, which ranges from 0 to 13.13 
The FAS is a questionnaire with 25 yes/no items, which screens an individual’s capacity to 
complete specific tasks independently (range 0-25). The IS assesses functional ability with 
one single score, ranging from 10 (tube-fed, total bed care) to 100 (no special care 
needed). For the three functional scores, lower scores indicate more functional decline. 
The motor domain of the UHDRS-FAP consists of 14 items, such as walking around, 
capacity to transfer, eat, and wash independently, dysphagia, and tendon retraction 
(range 0-52).10 The cognitive score comprises functional and categorical matching of the 
Protocole Toulouse Montreal d’Evaluation des Gnosies Visuelles (PEGV)14, pointing, simple 
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commands, the Stroop test, orientation, participation in activities, imitation (apraxia) and 
automatic series. Somatic symptoms are measured by 10 items, which are hyperhidrosis, 
hypersalivation, incontinence, digestion, hypersomnia and pressure ulcers (range 0-28). 
Behavioral abnormalities are examined by 8 yes/no items about the presence of 
psychiatric symptoms (range 0-8). Higher scores on the motor, somatic and behavioral 
domains indicate a higher level of impairment. For the cognitive domain, lower scores 
indicate more cognitive decline. 
The CDS is a questionnaire completed by nurses and includes 15 items on different aspects 
of care dependency, such as eating and drinking, day-night rhythm, dressing, avoiding 
danger, and learning ability.12 All items are rated on a 1-5 point scale, resulting in a total 
score ranging from 15 (completely dependent on care) to 75 (almost independent of care). 
 
Statistical analysis 
Demographic data and mean scores of the UHDRS and UHDRS-FAP domains and CDS were 
calculated at baseline. At follow-up six months later, the mean scores were calculated 
again and compared with baseline for the patients who participated twice using paired t-
tests. Change over time was also calculated for the different tests of the UHDRS cognitive 
section separately, since these assessments measure different elements of cognition. 
Responsiveness of the domains was determined by effect sizes (ESs) and standardized 
response means (SRMs). An ES of 0.20 was considered small, an ES of 0.50 moderate and 
an ES of 0.80 large.15 Additionally, participants were classified according to their TFC stage. 
TFC stages define the severity of HD and derive from the TFC subscale of the UHDRS: stage 
1, TFC 11-13; stage 2, TFC 7-10; stage 3, TFC 3-6; stage 4, TFC 1-2; stage 5, TFC 0.13 Higher 
TFC stages indicate worse functional capacity. Longitudinal changes of the UHDRS and 
UHDRS-FAP subscores and CDS score were calculated for TFC stage 4-5 (late stage) and 
TFC stage 2-3 (middle stage) using Wilcoxon signed-rank tests. A p-value of <0.05 was 
considered statistically significant. Data analysis was performed using IBM Statistical 
Package for the Social Sciences (SPSS, Leiden, The Netherlands) version 23. 
 
Results 
At baseline 40 HD patients participated in our study. After six months, 29 of them 
participated again, of whom 21 resided in a long-term care facility and 8 received day-
care. Eleven patients were lost to follow-up due to death (three), participation in an 
interventional medical trial (one) or withdrawal of consent (seven) for the following 
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reasons: assessments too confrontational (three) or too exhausting (two), or deterioration 
of HD (two). Demographic data at baseline are shown in Table 1 for all 40 participants and 
for the 29 patients who participated twice. Demographics at baseline were similar 
between the two groups. At baseline and follow-up 27 of the 29 patients used medication 
for HD symptoms, such as antidepressants, antipsychotics, and tetrabenazine. Medication 
was stable between the two evaluations in 18 patients and changed in 9 patients (starting 
or stopping medication, increase or decrease in dosage, or a combination of these 
options). Change in medication was equally distributed across the TFC stages. 
Table 2 reports the mean scores of all sections of the UHDRS, UHDRS-FAP and CDS at 
baseline and follow-up. Mean time interval between the two visits was 6.0 months (SD 
±0.5 months). The FAS (mean difference -1.4, 95% confidence interval (CI) -2.2--0.6, p = 
0.001) and IS (mean difference -2.8, 95%CI -5.0--0.5, p = 0.018) of the UHDRS and the CDS 
(mean difference -3.2, 95%CI -5.9--0.5, p = 0.022) declined significantly during six months’ 
follow-up. The motor (mean difference 1.9, 95%CI 0.2-3.8, p = 0.028) and cognitive score 
(mean difference -8.7, 95%CI -16.8--0.7, p = 0.034) of the UHDRS-FAP also deteriorated 
over time, in contrast to the motor and cognitive score of the UHDRS which did not show 
change. Concerning the cognitive domains of both scales, only the Stroop word reading 
component declined significantly during follow-up (mean difference -4.7, 95%CI -8.3--1.2, 
p = 0.011). The responsiveness analysis, including ES and SRM, is presented in Table 2. The 
ES and SRM were mostly small, except for the SRM of the FAS, which was moderate (-
0.67). 
 
Table 1. Demographic data of the participants at baseline 
 All HD patients (n = 40) HD patients who 
participated twice (n = 29) 
Age, years 54.5 (±12.8) 53.8 (±13.2) 
Male/female (%male) 14/26 (35.0%) 9/20 (31.0%) 
CAG repeat length 44.8 (±3.8)a 44.4 (±3.6) 
Educational level, years 13.3 (±2.9) 13.6 (±3.0) 
Age of disease onset, years 40.7 (±11.3) 40.7 (±11.4) 
Disease duration, years 13.4 (±5.1) 12.7 (±4.9) 
Data are mean (± standard deviation), except for gender (number, %). 
CAG, cytosine-adenine-guanine; HD, Huntington’s disease. 
a CAG repeat length was missing for two patients; they tested positive for HD through linkage analysis. 
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Table 3. Longitudinal data of the participants categorized by TFC stage 
  TFC stages 2-3 (n = 19) TFC stages 4-5 (n = 10) 









UHDRS Motor score 2.1 (-1.6-5.8) 0.251 0.4 (-5.9-6.7) 0.441 
 Cognitive score -1.6 (-11.5-8.3) 0.825 -16.0 (-30.6--1.4) 0.012 
 Behavioral score 1.3 (-1.9-4.4) 0.409 -5.6 (-9.4--1.8) 0.015 
UHDRS-FAP Motor score 1.6 (-0.3-3.6) 0.102 2.4 (-1.4-6.2) 0.138 
 Cognitive score -4.3 (-13.2-4.6) 0.344 -17.2 (-34.4-0.1) 0.047 
 Somatic score -0.2 (-1.6-1.3) 0.728 1.8 (-1.7-5.3) 0.437 
 Behavioral score 0.9 (0.5-1.4) 0.002 -0.9 (-1.8-0.0) 0.047 
CDS   -3.4 (-7.0-0.1) 0.064 -2.8 (-7.8-2.2) 0.673 
Mean differences (95% CI) between baseline and follow-up six months later are shown. The participants are 
categorized by TFC stage. p-values were calculated using Wilcoxon signed-rank tests. Significant differences 
(p<0.05) are shown in bold. 
CDS, Care Dependency Scale; CI, confidence interval; TFC, Total Functional Capacity; UHDRS, Unified 
Huntington's Disease Rating Scale; UHDRS-FAP, Unified Huntington's Disease Rating Scale-For Advanced 
Patients. 
 
Table 3 shows the mean differences of the UHDRS, UHDRS-FAP and CDS sections between 
the two time points for the different TFC stages. For HD patients in TFC stages 2-3 (middle 
stage) only the behavioral score of the UHDRS-FAP worsened significantly over time (mean 
difference 0.9, 95%CI 0.5-1.4, p = 0.002). For patients in TFC stages 4-5 (late stage) the 
cognitive score of both the UHDRS (mean difference -16.0, 95%CI -30.6--1.4, p = 0.021) 
and UHDRS-FAP (mean difference -17.2, 95%CI -34.4-0.1, p = 0.047) declined significantly 
and, interestingly, the behavioral score of both rating scales improved (UHDRS, mean 
difference -5.6, 95%CI -9.4--1.8, p = 0.015; UHDRS-FAP, mean difference -0.9, 95%CI -1.8-
0.0, p = 0.047). 
 
Discussion 
In this study, 29 advanced HD patients who received day-care or resided in a long-term 
care facility were examined longitudinally. Our results showed that the motor and 
cognitive score of the UHDRS-FAP deteriorated during six months’ follow-up, whilst the 
motor and cognitive score of the UHDRS did not show change. This finding suggests that 
69 Longitudinal assessment in late stage HD |
 
Table 3. Longitudinal data of the participants categorized by TFC stage 
  TFC stages 2-3 (n = 19) TFC stages 4-5 (n = 10) 









UHDRS Motor score 2.1 (-1.6-5.8) 0.251 0.4 (-5.9-6.7) 0.441 
 Cognitive score -1.6 (-11.5-8.3) 0.825 -16.0 (-30.6--1.4) 0.012 
 Behavioral score 1.3 (-1.9-4.4) 0.409 -5.6 (-9.4--1.8) 0.015 
UHDRS-FAP Motor score 1.6 (-0.3-3.6) 0.102 2.4 (-1.4-6.2) 0.138 
 Cognitive score -4.3 (-13.2-4.6) 0.344 -17.2 (-34.4-0.1) 0.047 
 Somatic score -0.2 (-1.6-1.3) 0.728 1.8 (-1.7-5.3) 0.437 
 Behavioral score 0.9 (0.5-1.4) 0.002 -0.9 (-1.8-0.0) 0.047 
CDS   -3.4 (-7.0-0.1) 0.064 -2.8 (-7.8-2.2) 0.673 
Mean differences (95% CI) between baseline and follow-up six months later are shown. The participants are 
categorized by TFC stage. p-values were calculated using Wilcoxon signed-rank tests. Significant differences 
(p<0.05) are shown in bold. 
CDS, Care Dependency Scale; CI, confidence interval; TFC, Total Functional Capacity; UHDRS, Unified 
Huntington's Disease Rating Scale; UHDRS-FAP, Unified Huntington's Disease Rating Scale-For Advanced 
Patients. 
 
Table 3 shows the mean differences of the UHDRS, UHDRS-FAP and CDS sections between 
the two time points for the different TFC stages. For HD patients in TFC stages 2-3 (middle 
stage) only the behavioral score of the UHDRS-FAP worsened significantly over time (mean 
difference 0.9, 95%CI 0.5-1.4, p = 0.002). For patients in TFC stages 4-5 (late stage) the 
cognitive score of both the UHDRS (mean difference -16.0, 95%CI -30.6--1.4, p = 0.021) 
and UHDRS-FAP (mean difference -17.2, 95%CI -34.4-0.1, p = 0.047) declined significantly 
and, interestingly, the behavioral score of both rating scales improved (UHDRS, mean 
difference -5.6, 95%CI -9.4--1.8, p = 0.015; UHDRS-FAP, mean difference -0.9, 95%CI -1.8-
0.0, p = 0.047). 
 
Discussion 
In this study, 29 advanced HD patients who received day-care or resided in a long-term 
care facility were examined longitudinally. Our results showed that the motor and 
cognitive score of the UHDRS-FAP deteriorated during six months’ follow-up, whilst the 
motor and cognitive score of the UHDRS did not show change. This finding suggests that 
 
these sections of the UHDRS-FAP can detect disease progression in late stage HD, contrary 
to the same sections of the UHDRS, which is probably caused by the ceiling and floor 
effects of the UHDRS. Therefore, the UHDRS-FAP motor and cognitive domains seem more 
suitable for optimizing care for patients with late stage HD, especially in nursing homes. 
The lack of change on the UHDRS domains could be due to the fact that medication was 
changed in some patients; however, the UHDRS-FAP domains did deteriorate. The UHDRS-
FAP motor score can be used to monitor change over time and to evaluate the effect of 
medication or therapy (physiotherapy, speech therapy, occupational therapy) in advanced 
HD, which is useful in clinical care but can also be used for research purposes. In addition, 
administration of this domain is minimally demanding as it only takes a few minutes. 
Youssov et al.10 detected motor and cognitive deterioration over time in patients with late 
stage HD with both the UHDRS-FAP and UHDRS, but the slope was steeper with the 
UHDRS-FAP, also suggesting that disease progression in advanced HD is better detected by 
the UHDRS-FAP than the UHDRS. Previous studies have shown decline in motor and 
cognitive performance on the UHDRS, but these studies were not performed in late stage 
HD.3-6 A different longitudinal study on all UHDRS cognitive tasks demonstrated 
deterioration through all consecutive TFC stages except from TFC stage 4 to 5, confirming 
the floor effect of the UHDRS cognitive section in advanced HD.9 The same study showed 
that the Stroop word reading test declined most rapidly over time from premanifest HD to 
TFC stage 5. This item, which is part of both the UHDRS-FAP and UHDRS, was also the only 
cognitive task that worsened in our cohort of patients with late stage HD and therefore 
supports the use of the Stroop word reading test for detecting disease progression. 
Of the three functional UHDRS subsections, the FAS and IS declined significantly during six 
months’ follow-up in our cohort of advanced HD patients; the TFC did not. Decline of FAS 
and IS scores are in line with previous longitudinal studies.3-5 However, these studies also 
reported decline of the TFC score. The reason for this discrepancy is probably the fact that 
their patients were in a less advanced stage of HD than our patients, since TFC scores 
deteriorate less rapidly in late stage HD (TFC stages 4 and 5) due to floor effects of the 
scale.8 Over six months’ time, the CDS also worsened significantly. Other studies in long-
term care facilities have shown that the CDS declined in patients with dementia, and to a 
lesser extent in patients without dementia.16,17 Our results indicate that the FAS, IS and 
CDS can be implemented in nursing home care to detect disease progression and 
individual problems in patients with late stage HD. 
Instead of only determining the statistically significant differences over time, these 
differences were also quantified with a responsiveness analysis. This analysis showed that 
the ES and SRM of the UHDRS and UHDRS-FAP domains, and the CDS were mostly small, 
except for the SRM of the FAS which was moderate. However, small values were expected 
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since the follow-up time was short and therefore the mean differences of the scores 
between the visits small. Probably, a longer follow-up time will lead to higher ES and SRM. 
The behavioral score of the UHDRS and UHDRS-FAP significantly improved after six 
months’ follow-up in HD patients in TFC stages 4 and 5. These results suggest that 
psychiatric symptoms in advanced HD patients fade away as disease duration progresses. 
However, previous longitudinal behavioral assessment in late stage HD did not show 
change on the UHDRS and UHDRS-FAP.10 Other studies have demonstrated that apathy 
increased as disease duration and TFC stage progressed18-20, whereas depression was 
more common in the mild-to-moderate disease severity stages.20,21 Depression and 
anxiety may diminish in later stages of the disease as emotions decrease and insight 
lessens, explaining our results. However, it is important to note that of the 11 HD patients 
who were lost to follow-up, 10 patients were in TFC stages 4 and 5. So, nearly all dropout 
occurred in the most advanced stages, which may have caused bias. 
A strength of our study is the administration of the UHDRS and UHDRS-FAP on the same 
day, so day-to-day variation of patients’ symptoms was excluded. In general, longitudinal 
research is challenging in nursing homes, because patients are in the last phase of their 
lives and chance of dropout is high. This is especially difficult for rare diseases, like HD. 
Due to the high number of patients who were lost to follow-up our sample size was small, 
which is a limitation of our study. The short follow-up time of six months is also a 
limitation. Ideally, the assessments are repeated after 12, 18 and 24 months in order to 
examine how the scores of the rating scales evolve over a longer period of time. Another 
limitation is the administration of the rating scales by two raters, which may have 
influenced the results due to interrater reliability. Furthermore, not all caregivers were 
present at the study visits, which may have led to underreporting of symptoms by the 
patient due to reduced insight. 
In conclusion, our longitudinal study in patients with advanced HD in a long-term care 
facility showed that the motor and cognitive score of the UHDRS-FAP, the FAS and IS of 
the UHDRS, and the CDS deteriorated during six months’ follow-up. This finding suggests 
that these sections can detect disease progression in late stage HD. Therefore, these 
scores are recommended for use in nursing homes to optimize HD care by monitoring 
disease progression and by evaluating the effect of interventions in clinical care. The 
behavioral score significantly improved with both rating scales in patients in TFC stage 4-5, 
indicating that psychiatric symptoms fade away as the disease progresses. 
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Abstract 
Background: Huntington’s disease is a progressive, incurable neurodegenerative disorder 
and it is not possible to delay onset or progression of the disease. Consequently, the 
disease leads to functional decline and loss of independency and finally to 
institutionalization. 
Objective: The aim of this study is to identify factors which are associated with nursing 
home admission in patients with Huntington’s disease. 
Methods: The Unified Huntington’s Disease Rating Scale (UHDRS) and the UHDRS-For 
Advanced Patients (UHDRS-FAP) were administered in 28 nursing home residents and 12 
patients receiving day-care. Comparisons between the two groups were performed using 
Mann-Whitney U tests and Chi-square tests. The significantly different findings were fitted 
in individual univariate logistic regression models to determine which components were 
most predictive of institutionalization. 
Results: Day-care participants were more often married than nursing home residents (p = 
0.006) and were functionally more independent: the Functional Assessment Scale (p = 
0.022) of the UHDRS was significantly higher. Not being married was more predictive for 
nursing home admission than functional capacity in the regression models. 
Conclusions: Our results suggest that being married is protective for nursing home 
placement. Possibly, a caregiver living with a patient can assist with activities of daily living 
which the patient could not have done independently, resulting in being able to live at 
home longer. Providing support to unmarried patients, who do not have a caregiver living 
with them, by home care services specialized in Huntington’s disease might increase the 
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Huntington’s disease (HD) is a hereditary, progressive neurodegenerative disorder caused 
by a cytosine-adenine-guanine (CAG) trinucleotide repeat expansion in the Huntingtin 
gene on chromosome 4.1 The disease is clinically characterized by a triad of motor, 
cognitive, and psychiatric symptoms. These symptoms ultimately lead to functional 
decline and loss of independency as HD progresses into a more advanced stage. The mean 
age at disease onset is 30-50 years, with a mean disease duration of 17-20 years.2 HD is 
presently incurable and it is not possible to delay either onset or progression of the 
disease. Due to the progressive nature of the disease, it eventually becomes more difficult 
for care to be provided at home, which leads to admission in a nursing home. However, 
guidelines for management and care of advanced HD patients in long-term care facilities 
are limited and only discuss different views on nursing home placement and treatment.3 
Demographically HD patients in nursing home facilities are younger (45-59 years)4-7 than 
the average nursing home resident (83-85 years)8,9, and therefore the need for care is 
different. Previous studies have shown that motor dysfunction, impaired activities of daily 
living (ADL), and reduced scores on the Mini-Mental State Examination (MMSE) were 
predictors of institutionalization in HD.5,6 Psychiatric symptoms did not predict nursing 
home placement. However, these studies were conducted retrospectively and only one 
study5 used the Unified Huntington’s Disease Rating Scale (UHDRS), which is most 
commonly used for the clinical assessment of symptoms and signs in HD.10 
Identification of predictors for institutionalization may lead to interventions and 
treatment strategies that can postpone the need for nursing home placement. 
Additionally, characterization of HD specific problems in nursing home residents could 
optimize their care. Therefore, the aim of this present study is to examine the differences 
between nursing home residents and day-care participants with HD, using the UHDRS and 
UHDRS-For Advanced Patients (UHDRS-FAP), which is developed for patients with late 
stage HD.11 We hypothesize that both nursing home residents as well as day-care 
participants are in an advanced stage of HD, and therefore we aim to examine which 
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Materials and methods 
 
Setting and participants 
Our study was carried out at the Huntington Center Topaz Overduin (Katwijk, the 
Netherlands), which is a nursing home with 70 residents, 20 day-care patients, and over 
100 outpatients, specialized in the care for HD patients, both in late and early stages. 
Specialized medical doctors, therapists, psychologists, and nurses provide long-term care 
and day-care, organize activities, and offer support for patients (and their family) who live 
at home. The long-term care facility comprises three departments: one department is 
specialized in psychiatric problems, one department provides care for patients highly 
dependent on care, and one department provides care for patients less dependent on 
care. Institutionalized patients and patients receiving day-care, with a clinically and/or 
genetically confirmed diagnosis of HD, were asked to participate in this study. The local 
medical ethics committee approved the study and written informed consent was obtained 
from all participants or their caregivers. Assessments performed in this study include the 
UHDRS, followed by the UHDRS-FAP on the same day. The scales were administered by 
two medical doctors experienced with HD. They interviewed and examined the patients, 
preferably in the presence of their caregiver. 
 
Assessments 
The UHDRS consists of four domains, which are motor function, cognitive function, 
behavioral abnormalities, and functional capacity.10 The motor section comprises 31 items 
assessing chorea, dystonia, eye movements, bradykinesia/rigidity, and gait/balance.10 All 
items are rated on a 0 to 4 point scale with 4 indicating the most severe impairment. The 
range of the Total Motor Score (TMS) is 0-124, with higher scores indicating more motor 
disturbances. The cognitive domain consists of the Verbal Fluency test12, the Symbol Digit 
Modalities test13, and the Stroop test (color naming, word reading, and interference).14 
Higher scores indicate better cognitive performance. The behavioral component assesses 
the frequency and severity of 11 items, such as depression, anxiety, irritability, apathy, 
and other behavioral symptoms.10 The items are rated from 0 to 4 and the total score 
ranges from 0 to 88, with higher scores indicating more severe psychiatric abnormalities. 
The functional domain is composed of three subunits10: the Functional Assessment Scale 
(FAS) including 25 yes/no questions about common daily tasks (range 0-25), the 
Independence Scale (IS) measuring the level of independence with one single score (range 
10-100), and the Total Functional Capacity (TFC) assessing occupation, finances, domestic 
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Independence Scale (IS) measuring the level of independence with one single score (range 
10-100), and the Total Functional Capacity (TFC) assessing occupation, finances, domestic 
 
chores, ADL, and care level (range 0-13).15 Overall, higher functional scores indicate better 
function. 
The UHDRS-FAP is divided into four sections: motor, cognitive, somatic, and behavior.11 
Motor performance is measured by 14 items, such as walking around, capacity to transfer, 
eat, and wash independently, dysphagia, imitation synkinesias, and other motor 
components (range 0-52). The cognitive score includes functional and categorical 
matching of the Protocole Toulouse Montreal d’Evaluation des Gnosies Visuelles (PEGV)16, 
pointing, simple commands, the Stroop test, orientation, participation in activities, 
imitation (apraxia), and automatic series. The somatic domain comprises 10 items 
assessing hyperhidrosis, hypersalivation, incontinence, digestion, hypersomnia, and 
pressure ulcers (range 0-28). The behavioral subscale includes 8 yes/no questions about 
the presence of psychiatric abnormalities (range 0-8). Higher scores on the motor, 
somatic, and behavioral sections indicate more impairment, while higher scores on the 
cognitive domain indicate better performance. 
 
Statistical analysis 
Demographic differences between nursing home residents and day-care participants with 
HD were analysed using Mann-Whitney U tests or Chi-square tests. Median scores of each 
section of the UHDRS and UHDRS-FAP were calculated for the institutionalized patients 
and the patients receiving day-care. We also calculated a modified TFC without the care 
level-item, because this item automatically distinguishes between patients who are 
admitted to a long-term care facility and patients who receive day-care. Comparisons of 
the scores between the two groups were performed with Mann-Whitney U tests. For the 
scores of the UHDRS and UHDRS-FAP sections that were significantly different between 
nursing home residents and day-care participants, we calculated the frequencies of the 
items within the domain. The significantly different findings between the two groups were 
fitted in individual univariate logistic regression models to determine which components 
were most predictive of institutionalization. In order to compare the outcomes of the 
univariate regression models the scores were dichotomized at the median in high and low 
scores. A p-value of <0.05 was considered statistically significant. Data analysis was 
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Results 
Forty HD patients participated in our study, including 28 nursing home residents and 12 
day-care participants. Of the 28 nursing home residents, 12 came from the 21-bed low-
care unit (57%), 9 from the 29-bed high-care unit (31%), and 7 from the 20-bed psychiatry 
unit (35%). Twelve of the 20 day-care patients chose to participate (60%). Demographic 
data of the nursing home residents and day-care participants are shown in Table 1. Day-
care participants were more often married or had a domestic partnership than nursing 
home residents (p = 0.006). Marital status changed for three residents during admission, 
but was also significantly different between day-care participants and residents at the 
time of admission (p = 0.038). Other demographics, such as age and disease duration, 
were not significantly different between the two groups. Age and gender of study 
participants were similar to the age and gender of the patients who did not consent to 
participate in the study. Likewise, only 15 of all 70 nursing home patients were married 
(21.4%) compared to 14 of 20 day-care patients (70.0%) (p < 0.001). 
 
Table 1. Demographics for nursing home residents and day-care participants with 
Huntington’s disease 
  Nursing home 
residents (n = 28) 
Day-care participants 
(n = 12) 
p-value 
Age, years 57.5 (46.0-66.8) 51.5 (45.3-63.8) 0.512 
Gender, male/female 
(%male) 
8/20 (28.6%) 6/6 (50.0%) 0.193 
CAG repeat length 44.0 (42.0-47.3)a 44.0 (42.0-47.5) 0.938 
Educational level, years 12.0 (12.0-14.5) 14.5 (12.0-16.8) 0.074 
Age of disease onset, years 40.0 (31.3-49.8) 40.5 (33.3-49.3) 0.998 
Disease duration, years 13.0 (10.0-18.8) 11.5 (8.3-16.3) 0.202 
Residence duration, years 3.0 (1.3-5.0) NA NA 
Medication for HD, yes/no 
(%yes) 
26/2 (92.9%) 12/0 (100.0%) 0.342 
Married, yes/no (%yes) 8/20 (28.6%) 9/3 (75.0%) 0.006 
Data are median (IQ-range); except for gender, medication for HD, and married, which are number (%). p-
values were calculated using Mann-Whitney U tests; except for gender, medication for HD, and married, which 
were calculated using Chi-square tests. 
a CAG repeat length was missing for two nursing home residents; they tested positive for HD through linkage 
analysis. 
CAG, cytosine-adenine-guanine; HD, Huntington's disease; NA, not applicable; IQ, interquartile. 
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The median scores of the UHDRS and UHDRS-FAP sections for the institutionalized 
patients and patients receiving day-care are given in Table 2. The FAS (p = 0.022) and TFC 
(p = 0.011) of the UHDRS functional domain were significantly lower for nursing home 
residents compared to day-care participants, indicating a worse function. However, the 
modified TFC did not show a significant difference (p = 0.163). The scores of the other 
UHDRS sections and all UHDRS-FAP sections did not show any differences between the 
two groups. 
Figure 1 shows how many patients were able to perform the common daily tasks of the 
FAS independently, demonstrating that particularly number 13 (take own medications 
without help), 18 (walk to places in neighborhood without help), and 24 (use 
toilet/commode without help) were less frequently performed independently by nursing 
home residents. The logistic regression model with married/domestic partnership as 
independent variable showed that not being married (i.e. not having a partner) was 
predictive of institutionalization in patients with HD (p = 0.010, OR 7.50, 95%CI 1.60-
35.08), meaning that non-married patients were 7.50 times more likely to being
 
Table 2. Clinical characteristics of nursing home residents and day-care participants with 
Huntington’s disease 
  Nursing home 
residents (n = 28) 
Day-care participants 
(n = 12) 
p-
value 
UHDRS Motor score 75.0 (40.5-88.0) 49.0 (29.8-82.3) 0.115 
 Cognitive score 51.5 (10.0-96.8) 102.0 (51.5-148.8) 0.069 
 Behavioral score 12.5 (8.0-24.8) 17.0 (9.0-25.0) 0.610 
 Functional 
Assessment Scale 
7.5 (1.3-13.8) 13.5 (8.3-17.0) 0.022 
 Independence Scale 60.0 (36.3-65.0) 62.5 (52.5-70.0) 0.163 
 Total Functional 
Capacity 
1.0 (0.0-3.8) 3.5 (2.3-6.8) 0.011 
 Modified TFC 1.0 (0.0-3.8) 2.5 (1.3-5.8) 0.163 
UHDRS-FAP Motor score 13.0 (4.3-25.3) 8.0 (6.0-17.8) 0.512 
 Cognitive score 89.8 (51.8-139.9) 141.0 (90.3-167.5) 0.096 
 Somatic score 5.0 (1.3-13.0) 5.5 (2.3-9.0) 0.805 
 Behavioral score 2.0 (1.0-3.0) 1.0 (0.3-3.0) 0.531 
Data are median (IQ-range). p-values were calculated using Mann-Whitney U tests. 
UHDRS, Unified Huntington's Disease Rating Scale; UHDRS-FAP, Unified Huntington's Disease Rating Scale-For 
Advanced Patients; TFC, Total Functional Capacity; IQ, interquartile. 
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Figure 1. Percentage of nursing home residents and day-care participants being able to perform the common 
daily tasks of the Functional Assessment Scale independently. 
 
institutionalized than married patients. The univariate regression model with the 
dichotomized FAS score as independent variable showed that lower scores were also 
associated with institutionalization (p = 0.047, OR 4.64, 95%CI 1.02-21.00), but this 




This study identified associations between clinical characteristics of patients with 
advanced HD in day-care and in a nursing home. Our results showed that lower scores on 
the FAS of the UHDRS functional domain and not being married were related to 
institutionalization. Probably, lower functional capacity causes more dependency on care 
for common daily tasks, which ultimately leads to institutionalization. The association 
between lower functional capacity and nursing home placement is consistent with 
previous findings that the ADL scale is related to institutionalization.6 We did not find 
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correlations between institutionalization and motor disturbances, cognitive performance, 
and behavioral abnormalities on the UHDRS and UHDRS-FAP. This finding indicates that 
nursing home residents are not more affected by the triad of symptoms characteristic for 
HD then patients in day-care, suggesting that these symptoms do not cause 
institutionalization. Our findings contrast with the results of previous studies, which 
indicated bradykinesia, impaired gait, and impaired tandem walking of the UHDRS-TMS5, 
the Motor Impairment Score (MIS), and the MMSE6 as predictors for nursing home 
placement. Like our study, psychiatric symptoms were not shown to predict 
institutionalization in HD in these studies.5,6 However, in our study less patients from the 
nursing home department specialized in psychiatric problems chose to participate 
compared to the other departments, which may have underestimated the amount of 
psychiatric symptoms in the nursing home residents. 
The results of the individual univariate logistic regression analysis suggest that not being 
married is more predictive of institutionalization in HD patients than lower scores on the 
FAS. This finding implies that having a partner protects better against nursing home 
admission than higher functional ability. Possibly, a caregiver living with a patient assists 
with ADL tasks which the patient could not have done independently, resulting in being 
able to live at home longer than a patient without a caregiver living with the patient. 
Assistance with ADL tasks and care can also be provided by home care services or 
caregivers not living with a patient (usually their children), but this care is not available 24 
hours a day. For example, when a patient is not able to use the toilet independently or 
walk to places in the neighborhood independently (with the chance of wandering), (s)he 
usually needs supervision 24 hours a day by a partner or nursing home facility. HD patients 
are usually admitted to a nursing home when middle-aged.4-7 Accordingly, partners of HD 
patients are generally younger than partners of average nursing home residents. Younger 
partners may have a better health status than older partners and may, therefore, be 
better capable to provide care for the patient at home. However, younger partners usually 
have a job and, consequently, are often not home to take care of the patient. 
To our knowledge, no study has been performed investigating the influence of a 
partner/caregiver on institutionalization in HD. A systematic review in patients with 
dementia showed that married patients and patients living with their caregiver had a 
lower risk of nursing home placement.17 Greater dementia severity, older age, 
neuropsychiatric symptoms, impaired cognition, and more functional impairment were 
also predictors of long-term care admission.17,18 Additionally, caregiver burden and 
inability of the caregiver to care for the patient were stated as reasons for 
institutionalization by caregivers of patients with dementia. The reasons for admission 
varied between countries. For example, none of the French caregivers expressed inability 
to care as a reason for institutionalization in patients with dementia, while this category 
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was mentioned by 30% of the Spanish caregivers.18 Reasons for nursing home placement 
in HD could also differ between countries, due to the organization of nursing home care, 
financial costs, and cultural aspects. Therefore, our results may be hard to apply to other 
countries, where HD care is less well organized or more expensive than in the 
Netherlands. 
Ideally, identification of predictors for institutionalization lead to interventions and 
treatment strategies that postpone the need for nursing home placement. However, not 
having a partner cannot be changed. Providing support to unmarried HD patients, who do 
not have a caregiver living with them, by home care services specialized in HD might 
increase the chance of the best possible care in the own environment before 
institutionalization and postpone nursing home admission. The last question of the FAS is 
‘could subject’s care still be provided at home?’, which gives an overview of the 
examiner’s perception of the patient’s functional ability. The examiners answered this 
question with ‘yes’ in 39.3% of the institutionalized HD patients, suggesting that for almost 
40% of the institutionalized patients care could be provided at home if the patient had a 
suitable caregiver/partner. After nursing home placement, the FAS can provide 
information about a patient’s dependency on care easily and quickly, which could possibly 
optimize their care. For example, less than 50% of the nursing home residents were able 
to bath or dress themselves without help, but more than 50% of the patients were able to 
walk, use the toilet, or feed themselves without help. 
The strength of our study is the use of the UHDRS and UHDRS-FAP for the clinical 
assessment of the patients. These scales were developed especially for HD patients. A 
limitation of our study is the small sample size and, therefore, this study might be 
underpowered. Due to the small sample size, we could not perform a multivariate 
regression analysis and in the univariate regression models the ranges of the confidence 
intervals of the odds ratios were very wide. The use of two examiners is another limitation 
and could have influenced our results due to interrater reliability. For some patients the 
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Focus of this thesis 
In Huntington’s disease (HD), detecting the course of motor, cognitive, and psychiatric 
symptoms is of great importance. If the presence, severity, and progression of symptoms 
and signs can be detected, the effect of therapeutic interventions can be monitored, 
which is useful in HD research and in clinical care. However, to measure change of 
symptoms and signs accurately, reliable and valid assessment scales are necessary. For the 
detection and monitoring of clinical features different rating scales are used, since the 
symptoms and signs of HD change as the disease progresses from premanifest stage to 
advanced stage. Therefore, the main aim of this thesis was to investigate the 
measurement properties of the Unified Huntington’s Disease Rating Scale (UHDRS)1 and of 
the Unified Huntington’s Disease Rating Scale-For Advanced Patients (UHDRS-FAP)2 in 
various severity stages of HD and to give recommendations on which items or sections of 
the scales are, or are not, useful in which stage of the disease. 
 
Assessment of motor symptoms 
The clinical assessment of motor symptoms in HD is usually performed with the Unified 
Huntington’s Disease Rating Scale-Total Motor Score (UHDRS-TMS). The developers of the 
scale found a good interrater reliability, with an intraclass correlation coefficient (ICC) of 
0.94.1 Our study in a large cohort of raters, who participated in the annual online 
certification of the UHDRS-TMS, also showed a good, but lower, interrater reliability of the 
UHDRS-TMS (ICC = 0.847) (chapter 2). The lower interrater reliability in our study can 
more than likely be explained by the fact that the raters involved in our study had variable 
levels of experience, and were not all HD experts. Interestingly, we found a poor interrater 
reliability for all five dystonia items of the UHDRS-TMS (ICC < 0.400), suggesting that the 
rating of these items is difficult to interpret, probably as a consequence of the subjective 
nature of the response options (absent, slight, mild, moderate, or marked dystonia). 
Therefore, removing, changing, or combining some of the dystonia items, or providing 
clearer response options should be explored, as poor interrater reliability hampers the 
monitoring of progression of HD motor symptoms. A previous study on the internal 
consistency of the UHDRS-TMS showed that after elimination of all dystonia items the 
internal consistency hardly changed, thereby also questioning the importance of the 
dystonia items.3 We believe that the dystonia items can be omitted in patients with mild 
to moderate HD, and should only be examined in patients with advanced HD, as dystonia 
often arises as the disease progresses. The annual online certification of the UHDRS-TMS 
also showed that the percentage of motor items scored correctly dropped significantly 
between baseline and follow-up (from 87.8% to 86.4%). However, a decrease of 1.4% 
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seems only marginally relevant. We recommend that raters should watch the teaching 
video of the UHDRS-TMS before each certification to be reminded of the established 
standards. The online video system allowed us to examine the interrater reliability of the 
UHDRS-TMS for a large number of raters. However, the use of video recordings was also a 
limitation of our study, since the raters did not perform an actual physical examination 
themselves and in real life the clinical presentation of a patient usually varies. 
For the measurement of reliability, various parameters can be used, such as ICC, Cohen’s 
kappa, and percentage agreement. We did not use percentage agreement, because this 
parameter does not take chance agreement into account. A weighted kappa can be used 
for categorical variables, such as the items of the UHDRS-TMS. The rationale for a 
weighted kappa is that misclassifications between adjacent categories are less serious 
than those between more distant categories. However, given that calculating a weighted 
kappa is cumbersome and complicated, especially if multiple raters are involved, we used 
the ICC, because the ICC is equivalent to a weighted kappa if a quadratic weighting 
scheme is used.4,5 
Clinical diagnosis of HD is generally based on the appearance of motor symptoms. 
Therefore, the UHDRS-TMS is often used in HD gene carriers to distinguish between 
premanifest individuals and manifest patients for research purposes. However, 
oculomotor abnormalities have already been observed with eye-tracking equipment 
before disease onset.6-9 Our study in premanifest HD gene carriers and healthy controls 
showed that horizontal ocular pursuit was the only affected item of the UHDRS 
oculomotor domain in premanifest individuals near to HD onset compared to controls 
(chapter 3). This finding suggests that horizontal ocular pursuit can be used to detect early 
clinical signs of HD in individuals who are at risk for developing HD in a much easier way 
than eye-tracking equipment. The fact that the other oculomotor items of the UHDRS-TMS 
did not show any differences between premanifest individuals and controls does not 
necessarily mean that they are not present, but more likely implies that these items are 
not sensitive enough to detect oculomotor abnormalities in premanifest HD gene carriers. 
Apart from the UHDRS-TMS, other studies have focussed on more quantitative 
instruments to measure motor impairment, such as eye-tracking equipment, tongue force 
analysis, and quantitative-motor (Q-Motor) assessments.6,10,11 Research has shown that Q-
Motor measures were more sensitive than the UHDRS-TMS and exhibited no placebo 
effect.12 While these objective instruments are useful for research purposes, in clinical 
practice the UHDRS-TMS seems a more feasible assessment. 
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Assessment of patients with advanced HD 
Severity of HD is usually classified into five stages using the Total Functional Capacity (TFC) 
subscale of the UHDRS: stage 1 (TFC 11-13), stage 2 (TFC 7-10), stage 3 (TFC 3-6), stage 4 
(TFC 1-2), and stage 5 (TFC 0).13 In patients with advanced HD (TFC stages 4 and 5), ceiling 
and floor effects of the UHDRS hamper the monitoring of changes over time.14 Therefore, 
the UHDRS-FAP has been developed voor late stage HD.2 Our cross-sectional study in 
advanced HD patients, residing in a nursing home or receiving day-care, showed that the 
motor scores of the UHDRS-FAP and UHDRS were the only subscales with a significantly 
worse score in TFC stage 5 compared to TFC stage 4 (chapter 4). The range of the UHDRS-
FAP motor score was broader, the standard error of measurement (SEM) was lower, and 
the effect size r was higher than for the UHDRS motor score, suggesting that the UHDRS-
FAP motor score differentiates better between patients in the highest TFC stages than the 
UHDRS motor score. Therefore, this subscale can possibly improve disease monitoring 
and, subsequently, care in patients with late stage HD in long-term care facilities. The 
cognitive and behavioral domains of both scales did not differ between TFC stages 4 and 5, 
and do not seem useful for differentiating between patients with advanced HD. We found 
a high internal consistency and high interrater reliability for the motor and cognitive 
scores of both scales, confirming previous findings.1,2 The interrater reliability of the 
UHDRS-TMS in this study (ICC = 0.876) was similar to the one in our study on the UHDRS-
TMS certification (ICC = 0.847). The behavioral scores of both scales showed low-to-
moderate values for internal consistency and interrater reliability. This contradicts 
previous studies, which found high ICC values for an adjusted version of the UHDRS 
behavioral section.15,16 However, they used a ‘clinically relevant’ interrater reliability, 
which means only differences larger than one point were included. 
Our longitudinal study in late stage HD showed that the motor and cognitive scores of the 
UHDRS-FAP deteriorated during six months follow-up, while the motor and cognitive 
scores of the UHDRS did not show change (chapter 5). Previous research in late stage HD 
showed that both the UHDRS-FAP and UHDRS motor and cognitive scores deteriorated 
over time, but the slope was steeper with the UHDRS-FAP.2 Both studies suggest that 
disease progression in advanced HD is better detected by the UHDRS-FAP than the 
UHDRS. Therefore, we recommend the use of the UHDRS-FAP motor and cognitive scores 
in nursing homes to optimize HD care by monitoring disease progression and by 
evaluating the effect of interventions in clinical care. The Functional Assessment Scale 
(FAS) and Independence Scale (IS) of the UHDRS, and the Care Dependency Scale (CDS)17 
also worsened over six months’ time. Other studies in long-term care facilities also found a 
decline of the CDS in patients with dementia, and to a lesser extent in patients without 
dementia.18,19 Interestingly, the behavioral scores of the UHDRS-FAP and UHDRS improved 
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in HD patients in TFC stages 4 and 5, suggesting that psychiatric symptoms fade away as 
the disease progresses. Previous studies also showed that depression and anxiety diminish 
in more advanced HD as emotions decrease and insight lessens.20,21 Decline of psychiatric 
symptoms could also be caused partly by less communicative abilities of patients in late 
stage HD. Additionally, increased motor symptoms may lead to less strength and 
coordination to hit something, and therefore detection of irritability and agitation could 
be more complicated. For these reasons, the standard behavioral assessments do not 
seem suitable for advanced disease stages. 
In the same cohort of late stage HD patients, we also examined the demographical and 
clinical differences between nursing home residents and day-care patients (chapter 6). 
None of the UHDRS-FAP or UHDRS subscales showed differences between the two groups, 
except for the FAS. This functional scale of the UHDRS demonstrated more dependency on 
care for common daily tasks for the institutionalized patients compared to the day-care 
participants. Interestingly, the most predictive factor for nursing home admission was not 
being married. This finding implies that a partner can assist with common daily tasks 
which a patient could not have done independently, resulting in being able to live at home 
longer. A systematic review on patients with dementia also showed that married patients 
had a lower risk of nursing home placement than patients without a partner.22 Providing 
support to unmarried patients and their caregivers by home care services specialized in 
HD might increase the chance of the best possible care in the own environment before 
institutionalization and postpone nursing home admission. Furthermore, individual case 
management by social workers specialized in HD could also contribute to better care. 
Limitations of our studies in patients with advanced HD were the small sample size of 40 
participants and the administration of the rating scales by two raters, which may have 
influenced the results due to interrater reliability. 
 
Future perspectives 
The therapeutic interventions that are currently being developed and tested aim to slow 
down progression of HD. To measure change of clinical features accurately, reliable and 
valid assessment scales and measurement instruments are necessary. The UHDRS-TMS is 
widely used in therapeutic clinical trials and often serves as primary endpoint to assess 
efficacy of interventions. We showed that the UHDRS-TMS has a high interrater reliability, 
except for all dystonia items, which showed a poor interrater reliability. Future studies are 
required to explore how the dystonia items can be improved or to examine if objective 
motor assessments can measure dystonia more reliable than the UHDRS-TMS. 
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It is important to realize that sensitive assessment scales and measurement instruments 
differ from premanifest HD to early, moderate, and advanced HD. We demonstrated that 
for the identification of motor impairment in premanifest HD, horizontal ocular pursuit 
can be used, while the saccade initiation and saccade velocity items did not show deficits 
in premanifest HD. In late stage HD, however, we showed that the motor and cognitive 
sections of the UHDRS-FAP were more sensitive to detect changes than the motor and 
cognitive domains of the UHDRS. Although less interventional research is being performed 
in patients with advanced HD compared to patients in the early stages of the disease, the 
implementation of the UHDRS-FAP instead of the UHDRS in nursing homes to optimize 
clinical care is an important goal for the future. Additionally, the UHDRS-FAP should be 
investigated for a longer follow-up period. 
Recently, proposals have been made for the use of measurement instruments that relate 
to health as the ability to adapt and to self-manage.23 Therefore, we believe that the 
UHDRS-FAP should not only include sections on motor, cognitive, and behavioral 
symptoms, but should also assess functional status and include quality of life 
questionnaires. For the development of these sections, patients’ and caregivers’ input on 
what topics and questions should be included is important. 
Identification of predictors for institutionalization may lead to interventions and 
treatment strategies that postpone the need for nursing home admission. We 
demonstrated that not having a partner was associated with nursing home placement in 
HD. However, we did not collect additional information about the partners or questioned 
the partners independently from the patients. Future research on the role of caregivers, 
cultural aspects, and financial costs may identify more predictors for institutionalization in 
HD. This information is of great importance since HD patients are usually younger than the 
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Huntington’s disease (HD) is a progressive neurodegenerative disorder caused by an 
autosomal dominantly inherited cytosine-adenine-guanine (CAG) trinucleotide repeat 
expansion in the Huntingtin gene on chromosome 4. The disease is clinically characterized 
by motor impairment, cognitive decline, and behavioral symptoms. As HD progresses, the 
symptoms lead to functional decline and loss of independency. The mean age of disease 
onset is 30-50 years and mean disease duration is 17-20 years. HD is presently incurable 
and it is not possible to delay either onset or progression of the disease. 
In this thesis we have investigated measurement properties of the Unified Huntington’s 
Disease Rating Scale (UHDRS) and the Unified Huntington’s Disease Rating Scale-For 
Advanced Patients (UHDRS-FAP) in various severity stages of HD. These assessment scales 
have been developed to monitor the presence, severity, and progression of symptoms 
systematically over time. To measure change of symptoms accurately, reliable and valid 
scales are essential. The UHDRS consists of a motor, cognitive, behavioral, and functional 
domain. The UHDRS-FAP comprises a motor, cognitive, somatic, and behavioral section, 
and is especially designed for patients with advanced HD. 
The clinical assessment of motor symptoms in HD is usually performed with the Unified 
Huntington’s Disease Rating Scale-Total Motor Score (UHDRS-TMS). The UHDRS-TMS 
consists of 31 items assessing chorea, dystonia, eye movements, bradykinesia/rigidity, and 
gait/balance. All items are rated on a 0 to 4 point scale, with 0 indicating normal findings 
and 4 indicating severe abnormalities. A high interrater reliability is desirable for the 
monitoring of symptoms and, therefore, a teaching video and an annual online 
certification has been developed and implemented. We have investigated the interrater 
reliability of the UHDRS-TMS and of its subitems in 944 first-time participants, who took 
part in the online UHDRS-TMS certification (chapter 2). The UHDRS-TMS, tandem walking, 
pronate/supinate hands left, and retropulsion pull test showed good interrater reliability. 
Poor interrater reliability was found for dystonia of the trunk, dystonia of the left and right 
upper extremity, dystonia of the left and right lower extremity, tongue protrusion, and 
rigidity arms left. We concluded that the rating of these items is difficult to interpret, 
probably as a consequence of the subjective nature of the response options. Another 
important outcome of this study was that raters performed significantly worse on follow-
up certification compared to their first certification. Therefore, we recommended that 
raters should watch the UHDRS-TMS teaching video before each certification. 
For research purposes, the UHDRS-TMS is also used to distinguish between premanifest 
individuals (HD gene carriers who do not show symptoms yet) and manifest patients (HD 
gene carriers who have developed symptoms). We have examined if the oculomotor items 
of the UHDRS-TMS were affected in premanifest gene carriers compared to healthy 
controls (chapter 3), since oculomotor deficits have been detected by eye-tracking 
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equipment before HD onset. Seventy premanifest individuals and 27 controls were 
assessed. Horizontal ocular pursuit was the only oculomotor item that was more 
frequently affected in premanifest individuals near to HD onset compared to controls. 
Vertical ocular pursuit, horizontal and vertical saccade initiation, and horizontal and 
vertical saccade velocity did not show this. We hypothesized that only horizontal ocular 
pursuit is sensitive enough to detect early oculomotor deficits in individuals at risk for 
developing HD. 
In patients with advanced HD, ceiling and floor effects of the UHDRS hamper the 
monitoring of HD changes. Therefore, the UHDRS-FAP has been developed voor late stage 
HD. We have studied the properties of the UHDRS-FAP and UHDRS in 40 patients with 
advanced HD residing in a nursing home or receiving day-care (chapter 4). Both 
assessment scales were administered on the same day and were repeated after seven 
days by an independent medical doctor. Severity of HD was divided into five stages using 
the Total Functional Capacity (TFC) subscale of the UHDRS; stage 1 included patients with 
early HD and stage 5 included patients with advanced HD. The motor scores of the UHDRS-
FAP and UHDRS were the only subscales with significantly worse scores in TFC stage 5 
compared to TFC stage 4. Further investigation suggested that the UHDRS-FAP motor 
score differentiated better between patients in the highest TFC stages than the UHDRS 
motor score (UHDRS-TMS). We concluded that the UHDRS-FAP motor score can possibly 
improve disease monitoring and, subsequently, care in patients with late stage HD in 
nursing homes. Additionally, a high internal consistency and high interrater reliability were 
found for the motor and cognitive scores of both assessment scales. 
We have continued our study in advanced HD by administrating the UHDRS-FAP and 
UHDRS again after six months in 29 patients (chapter 5). The motor and cognitive scores 
of the UHDRS-FAP deteriorated during six months follow-up, while the motor and 
cognitive scores of the UHDRS did not show any change. This finding suggested that the 
UHDRS-FAP can detect disease progression in late stage HD, contrary to the UHDRS. 
Therefore, we recommended the use of the UHDRS-FAP motor and cognitive scores in 
long-term care facilities to optimize HD care by monitoring disease progression and by 
evaluating the effect of interventions in clinical care. The Functional Assessment Scale 
(FAS) and Independence Scale (IS) of the UHDRS functional domain, and the Care 
Dependency Scale (CDS) also declined over six months’ time. Interestingly, the behavioral 
scores of the UHDRS-FAP and UHDRS improved in HD patients in TFC stages 4 and 5. We 
hypothesized that psychiatric symptoms fade away as the disease progresses due to 
emotional blunting and decreased insight. 
In the same cohort of advanced HD patients, we have investigated the demographical and 
clinical differences between 28 nursing home residents and 12 patients receiving day-care 
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(chapter 6). Day-care participants were more often married than nursing home residents 
and were functionally more independent: the FAS was significantly higher. No correlations 
were found between institutionalization and motor disturbances, cognitive performance, 
and psychiatric symptoms. Not being married was the most predictive factor for nursing 
home admission. We concluded that a partner possibly assists with common daily tasks 
which a patient could not have done independently, resulting in being able to live at home 
longer. We hypothesized that providing support to unmarried patients by home care 
services specialized in HD may lead to interventions and treatment strategies that 
postpone the need for nursing home admission. 
In conclusion, HD motor symptoms were reliable assessed with the UHDRS-TMS. However, 
future studies are required to explore how the dystonia items can be improved. In 
patients with advanced HD, the UHDRS-FAP was more sensitive to detect changes over 
time than the UHDRS and should, therefore, be implemented in nursing homes. Marriage 
was a protector for nursing home admission. However, future research should focus on 
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De ziekte van Huntington (ZvH) is een progressieve neurodegeneratieve aandoening, die 
veroorzaakt wordt door een autosomale dominante overervende cytosine-adenine-
guanine (CAG) trinucleotide verlenging in het Huntingtine gen op chromosoom 4. De 
ziekte wordt klinisch gekarakteriseerd door motorische verslechtering, cognitieve 
achteruitgang en gedragsproblemen. Als de ZvH vordert, leiden de symptomen tot 
functionele achteruitgang en verlies van onafhankelijkheid. De gemiddelde leeftijd waarop 
de ziekte zich manifesteert is tussen de 30 en 50 jaar en de gemiddelde duur van de ziekte 
is 17 tot 20 jaar. De ZvH is op dit moment een ongeneeslijke ziekte en het is niet mogelijk 
om het begin van de ziekte uit te stellen, dan wel progressie van de ziekte te remmen. 
In dit proefschrift hebben we onderzoek gedaan naar de meeteigenschappen van de 
Unified Huntington’s Disease Rating Scale (UHDRS) en de Unified Huntington’s Disease 
Rating Scale-For Advanced Patients (UHDRS-FAP) in verschillende stadia van de ZvH. Deze 
scorelijsten zijn ontwikkeld om de aanwezigheid, ernst en progressie van symptomen 
systematisch te volgen over de tijd. Om verandering van symptomen nauwkeurig te 
meten, zijn betrouwbare en valide scorelijsten essentieel. De UHDRS bestaat uit een 
motorisch, cognitief, functioneel en gedragsdomein. De UHDRS-FAP omvat een motorisch, 
cognitief, somatisch en gedragsdomein, en is speciaal ontwikkeld voor patiënten met 
vergevorderde ZvH. 
De klinische beoordeling van motorische symptomen bij de ZvH wordt doorgaans verricht 
met behulp van de Unified Huntington’s Disease Rating Scale-Total Motor Score (UHDRS-
TMS). De UHDRS-TMS bestaat uit 31 items, waarmee chorea, dystonie, oogbewegingen, 
bradykinesie/rigiditeit en lopen/balans worden beoordeeld. Alle items kunnen gescoord 
worden van 0 tot en met 4, waarbij 0 ‘normale bevindingen’ en 4 ‘ernstige afwijkingen’ 
aangeeft. Om symptomen te meten is een hoge interbeoordelaarsbetrouwbaarheid 
wenselijk. Daarom is een onderwijsvideo en een jaarlijkse online certificatie ontwikkeld en 
ingevoerd. Wij hebben de interbeoordelaarsbetrouwbaarheid van de UHDRS-TMS en van 
de subitems onderzocht in 944 deelnemers die voor het eerst meededen aan de online 
UHDRS-TMS certificatie (hoofdstuk 2). De UHDRS-TMS, koorddansersgang, 
pronatie/supinatie linkerhand en de retropulsietest hadden een goede 
interbeoordelaarsbetrouwbaarheid. Een slechte interbeoordelaarsbetrouwbaarheid werd 
gevonden voor dystonie van de romp, dystonie van de linker- en rechterarm, dystonie van 
het linker- en rechterbeen, tongprotrusie en rigiditeit van de linkerarm. Wij concludeerden 
hieruit dat de scoring van deze items moeilijk te interpreteren is, waarschijnlijk als gevolg 
van de subjectiviteit van de antwoordmogelijkheden. Een andere belangrijke bevinding 
van dit onderzoek was dat de deelnemers significant slechter scoorden tijdens hun 
tweede certificatie vergeleken met hun eerste certificatie. We hebben daarom 
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In onderzoeksverband wordt de UHDRS-TMS ook gebruikt om onderscheid te maken 
tussen premanifeste personen (gendragers die nog geen symptomen hebben) en 
manifeste patiënten (gendragers die wel symptomen hebben ontwikkeld). We hebben 
onderzocht of de oogbewegingsitems van de UHDRS-TMS waren aangedaan in 
premanifeste gendragers vergeleken met gezonde controles (hoofdstuk 3), aangezien met 
gecomputeriseerde apparatuur afwijkingen van de oogbewegingen waren gevonden vóór 
het begin van de ZvH. Zeventig premanifeste personen en 27 controles werden 
onderzocht. Horizontale oogvolgbewegingen waren het enige oogbewegingsitem dat 
frequenter was aangedaan in premanifeste personen dichtbij begin van de ziekte 
vergeleken met controles. Voor de verticale oogvolgbewegingen, horizontaal en verticaal 
begin van de saccade en horizontale en verticale snelheid van de saccade gold dit niet. Wij 
veronderstelden dat horizontale oogvolgbewegingen als enige sensitief genoeg waren om 
beginnende afwijkingen van de oogbewegingen te detecteren bij risicodragers. 
Bij patiënten met vergevorderde ZvH belemmeren plafond- en bodemeffecten van de 
UHDRS het vastleggen van veranderingen. Voor patiënten in een laat stadium van de ZvH 
is daarom de UHDRS-FAP ontwikkeld. Wij hebben de eigenschappen van de UHDRS-FAP en 
de UHDRS onderzocht bij 40 patiënten met vergevorderde ZvH, die in een verpleeghuis 
woonden of daar dagbehandeling kregen (hoofdstuk 4). Beide scorelijsten werden 
afgenomen op dezelfde dag en werden na zeven dagen herhaald door een onafhankelijke 
arts. De ernst van de ZvH werd verdeeld in vijf stadia door middel van de Total Functional 
Capacity (TFC) schaal van de UHDRS; stadium 1 bestond uit patiënten met een vroeg 
stadium van de ZvH en stadium 5 bestond uit patiënten met een laat stadium van de ZvH. 
De motorische scores van de UHDRS-FAP en UHDRS waren de enige domeinen met een 
significant slechtere score in TFC stadium 5 vergeleken met TFC stadium 4. Verder 
onderzoek deed vermoeden dat de motorische score van de UHDRS-FAP beter 
differentieerde tussen patiënten in de hoogste TFC stadia dan de motorische score van de 
UHDRS (UHDRS-TMS). We hebben hieruit geconcludeerd dat de motorische score van de 
UHDRS-FAP mogelijk het monitoren van de ziekte kan verbeteren, en dientengevolge ook 
de zorg, bij patiënten in een laat stadium van de ZvH in verpleeghuizen. Daarnaast werden 
ook een hoge interne consistentie en hoge interbeoordelaarsbetrouwbaarheid gevonden 
voor de motorische en cognitieve scores van beide scorelijsten. 
We hebben onze studie in 29 patiënten met vergevorderde ZvH voortgezet door de 
UHDRS-FAP en UHDRS nogmaals af te nemen na zes maanden (hoofdstuk 5). De 
motorische en cognitieve scores van de UHDRS-FAP verslechterden na zes maanden, 
terwijl de motorische en cognitieve scores van de UHDRS niet veranderden. Deze uitkomst 
impliceert dat de UHDRS-FAP, in tegenstelling tot de UHDRS, ziekteprogressie kan 
detecteren bij patiënten in een laat stadium van de ZvH. We hebben daarom geadviseerd 
om de motorische en cognitieve scores van de UHDRS-FAP te gebruiken in verpleeghuizen 
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om de zorg te verbeteren door middel van het meten van ziekteprogressie en het 
evalueren van het effect van interventies. De Functional Assessment Scale (FAS) en de 
Independence Scale (IS) van het functionele domein van de UHDRS en de Care 
Dependency Scale (CDS) verslechterden ook na zes maanden. De gedragsscores van de 
UHDRS-FAP en de UHDRS verbeterden juist bij patiënten met de ZvH in TFC stadia 4 en 5. 
Wij vermoedden dat psychiatrische symptomen afnemen door emotionele vervlakking en 
afgenomen ziekte-inzicht als de ziekte vordert. 
In hetzelfde cohort van patiënten met vergevorderde ZvH hebben we de demografische 
en klinische verschillen onderzocht tussen 28 verpleeghuisbewoners en 12 patiënten die 
dagbehandeling kregen (hoofdstuk 6). De deelnemers met dagbehandeling waren vaker 
getrouwd dan de verpleeghuisbewoners en waren zelfstandiger: de FAS was significant 
hoger. Er werden geen correlaties gevonden tussen verpleeghuisopname en motorische 
verschijnselen, cognitieve prestaties en psychiatrische symptomen. Niet getrouwd zijn had 
de grootste voorspellende waarde voor verpleeghuisopname. We concludeerden hieruit 
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